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Abstract  
The benefits of increased physical activity on well-being for women with early stage breast cancer are well understood. However, its 
role for women living with metastatic disease is unknown due to their exclusion from physical activity and exercise research. The 
omission of this population from trials is primarily due to fear of skeletal-related events and high symptom burden. Having identified 
gaps in the knowledge about physical activity for women with metastatic breast cancer, the program of research herein was 
developed. Broadly, the aims of this thesis were to determine the physical capabilities and interests for physical activity of women 
living with metastatic breast cancer and to use this information to develop and pilot an appropriate physical activity intervention. In 
addition, it was identified that the accuracy of devices for measuring physical activity in this older age group was unknown, which led 
to the design of the final study to assess the accuracy of three physical activity monitors.   
The first step towards designing an intervention was to understand the physical capabilities of women living with metastatic breast 
cancer. The first study aimed to describe physical function and fitness of this population in comparison to an age-matched healthy 
cohort. Patient-reported outcomes and physical measures of strength and fitness were obtained from 71 women with metastatic 
breast cancer and 71 healthy controls. Women with metastatic cancer possessed lower levels of fitness and less muscle strength than 
the healthy women. The metastatic group were also only around half as active as the healthy cohort, also experiencing higher 
symptom burden. There was a large variation in physical function observed in the cancer cohort, with many women exceeding the 
average fitness for their age.    
In the development of an exercise program, consideration of the interests and preferences for physical activity is also important for 
enhancing efficacy and adherence. Through a structured interview, the second study aimed to determine physical activity preferences 
and to identify perceived barriers and benefits to activity in 62 women with metastatic breast cancer. The majority of women were 
interested in a program designed to increase physical activity and identified a strong preference for home-based activity. The most 
favoured type of activity was walking. Barriers included other commitments, pain and lack of motivation, with increased energy the 
most common perceived benefit of commencing a program.  
With the exclusion of women with metastatic breast cancer from physical activity interventions, the safety and feasibility of such 
programs is relatively unknown. With an understanding of physical capacity and programming preferences obtained through the first 
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two studies, an intervention to address this gap was developed. The primary aim of the third study was to evaluate the safety and 
feasibility of a home-based program comprising of supervised resistance training and an unsupervised walking program. Fourteen 
women were randomised to either a control group or the physical activity intervention. Recruitment and retention rates were 
excellent, with no adverse events reported. There was high adherence and compliance to resistance training, but these were poor in 
the walking component. Trends in favour of the exercise group over the control group were observed for measures of physical 
function and symptom burden.   
Throughout the first three studies, the measurement of physical activity was fundamental. One popular choice for researchers to 
capture activity levels is physical activity monitors. It was, however, identified that there is limited data to support their use in free-
living in women of a similar age to those with metastatic breast cancer. The fourth study, therefore, aimed to establish the accuracy 
of the Actigraph™, SenseWear® and ActiHeart® physical activity monitors in older women in free-living. Thirty-three women wore the 
three devices for 14 days, and energy expenditure estimated by each device was compared to the reference method of doubly 
labelled water. At the group level, all three monitors demonstrated acceptable agreement for total energy expenditure but 
demonstrated larger error when capturing physical activity energy expenditure. When measuring energy expenditure in women over 
50 years, the Actigraph™ was recommended as the preferred device, owing to its relatively superior performance and affordability. 
In conclusion, the findings from this thesis inform clinicians and researchers that despite the heterogeneity of the metastatic breast 
cancer population, most women are interested and capable of being physically active. The finding that a partially supervised 
resistance and walking program is safe for this population adds further evidence to the limited knowledge in this area. In addition, 
physical activity may also be beneficial for improving well-being and helping women to manage their disease. With respect to the 
accurate assessment of physical activity, this thesis recommends the use of the Actigraph™ in older women.  
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Preface 
The work presented in this thesis consists of six chapters. Chapter 1 provides an introduction to metastatic breast cancer, its 
treatment and associated symptom burden. It also presents an overview of current scientific knowledge about the role of exercise 
and physical activity in both early and metastatic breast cancer. To inform an appropriate physical activity program for women with 
metastatic breast disease, an understanding of the physical capabilities of the population was required. Chapter 2 describes physical 
activity levels and fitness of this population in comparison to a healthy age-matched cohort. To further assist in the intervention 
design, interests and preferences for physical activity were explored in Chapter 3. With the information obtained in Chapters 2 and 3, 
a physical activity intervention was developed and piloted in Chapter 4. The final study, Chapter 5, investigates the validity of three 
physical activity monitors in older women, to inform future research in women living with metastatic breast cancer. Chapter 6 
presents the concluding remarks for the thesis.  
Chapter 2 contains an article published in the Journal of Cancer Survivorship. The language and formatting of this chapter are 
appropriate to the journal it was submitted. The remaining chapters will be submitted for publication in the near future. 
All studies reported herein received ethical approval from the relevant Human Research Ethics Committees prior to commencing 
(Appendix). All women provided written informed consent prior to participation.  
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Chapter 1:  
Introduction  
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Breast cancer 
Cancer is a leading cause of illness, placing a substantial burden on individuals, families and the community. In Australia, the most 
commonly diagnosed cancer in females is breast cancer, and the risk of being diagnosed before the age of 85 is 1 in 8 [1]. In 2014, 
there were 15,270 cases of breast cancer in Australia [2], with this estimated to reach 17,210 in 2020 [1]. Whilst the incidence of 
breast cancer continues to rise, advances in detection and treatment for breast cancer mean that five-year relative survival has 
increased from 72% in 1982-86 to 89% in 2006-2010 [1]. In 2014 it is estimated that 3030 deaths in Australia resulted from breast 
cancer [2]. 
Although the causes of breast cancer are not well understood, various risk factors for its development have been identified. Female 
sex is a significant risk factor, along with increasing age and family history [3]. Lifestyle factors such as obesity and high alcohol 
consumption, particularly among post-menopausal women, contribute to increased breast cancer risk [1]. Menstrual and 
reproductive events are also established risk factors, with parity and breastfeeding providing a protective effect [3]. A review of over 
50 epidemiological studies also reported an inverse association between physical activity and breast cancer risk, with the greatest 
reduction in risk seen at higher levels of activity [4].     
Metastatic breast cancer 
Metastatic cancer, also often referred to as secondary, advanced or stage IV cancer, occurs when cancer spreads from the original 
tumour to other parts of the body. In breast cancer, the most common site for metastasis is bone, followed by liver, lung and brain 
[5]. Of women who present with an initial diagnosis of early breast cancer, approximately 10% will go on to develop metastatic 
disease within 5 years [5]. In addition, 5-10% of women present with metastatic disease at the time of the initial diagnosis [6].  
For women with metastatic breast cancer, the median survival is 2-3 years [7, 8]. However, individual survival is highly variable and 
can span from months to several years depending on tumour characteristics and location of metastases. For women with metastatic 
disease in Australia, data suggest that the five-year relative survival is around 40% [9]. Advancements in diagnosis and treatment for 
metastatic breast cancer has been impressive over the past few decades, leading to an increased number of therapies available for 
managing the disease [10]. These advances have resulted in a decline in breast cancer mortality, with many women now living for 
extended periods of time [2].    
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Treatment for metastatic breast cancer and related side-effects 
Metastatic breast cancer is a heterogeneous disease with an unpredictable clinical course, making medical management extremely 
complex [10, 11]. The choice of treatment takes into consideration a number of factors such as the patient’s age, menopausal status, 
comorbidities, performance status, psychosocial factors and treatment preferences. Other factors include the hormone receptor and 
human epidermal growth factor receptor 2 (HER2) status of the tumour, previous therapies and treatment response, disease-free 
interval, efficacy and toxicity of treatment [10]. Of particular importance is the location of metastatic lesions as women with bone-
only metastases have a more favourable prognosis than those with spread to the viscera [11, 12]. Due to the heterogeneity of 
metastatic breast cancer and the many factors that influence treatment decisions, the treatment course varies substantially between 
individuals. The goals of treatment for metastatic breast cancer are not curative but aim for prolonged survival, disease control, relief 
of symptoms and improvement in quality of life [13, 14].   
Endocrine Therapy 
In Western countries, hormone receptor-positive tumours account for approximately 70% of all breast cancer cases [15]. The 
recommended first-line treatment for these women is endocrine therapy, unless there is proven endocrine resistance or severe organ 
dysfunction [11, 13]. As oestrogen can contribute to the growth of cancer, endocrine therapy works by interfering with oestrogen 
stimulation of breast cancer cells [16]. There are currently three commonly used classes of therapy; i) selective oestrogen receptor 
modulators that block oestrogen receptors but continue to mimic oestrogen effects (e.g. tamoxifen), ii) third-generation aromatase 
inhibitors, which reduce circulating oestrogen (e.g. anastrozole and exemestane), and iii) oestrogen receptor down-regulators that 
block oestrogen receptors and destroy them (e.g. fulvestrant) [17]. Many women benefit from the sequential use of endocrine 
therapies, with aromatase inhibitors the preferred first-line for those who are postmenopausal and fulvestrant as second-line therapy 
[15]. For premenopausal women, ovarian suppression or ablation may be offered in combination with endocrine therapy [18].  
Whilst endocrine therapy is generally well-tolerated, there are several unfavourable symptoms that may present. Common but mild 
side effects of tamoxifen include hot flushes and irregular periods, with blood clots and uterine cancer reported in rare cases [17]. 
Women who take aromatase inhibitors are at an increased risk of osteoporosis, musculoskeletal symptoms and bone fracture [17]. 
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Such side effects have the potential to exacerbate other chronic conditions, highlighting the importance of treatment selection in the 
presence of comorbidities.  
Chemotherapy 
Despite considerable side-effects, cytotoxic chemotherapy still plays a major role in managing metastatic breast cancer [11, 19]. 
Candidates for chemotherapy include those with hormone-negative tumours, bulky visceral disease, severe tumour-related 
symptoms or rapidly progressing disease [11, 20]. Cytotoxic chemotherapy is designed to destroy cancer cells, but in the process, 
normal cells are also damaged causing treatment toxicity. To manage this, multidrug regimens are often replaced with sequential 
single-agent therapies that reduce toxicity and allow for continued participation in daily life [11, 19, 21].  
There are four preferred single cytotoxic agents for the treatment of metastatic breast cancer; anthracyclines (e.g. doxorubicin, 
epirubicin), taxanes (e.g. paclitaxel, docetaxel), anti–metabolites (e.g. capecitabine, gemcitabine) and non-taxane microtubule 
inhibitors (e.g. eribuline, vinorelbine) [18]. Traditionally, chemotherapy has been short-term with agents administered intravenously. 
However, this has shifted over the past decade to longer-term treatment with the emergence of cytotoxic oral agents such as 
capecitabine and vinorelbine [22]. These oral treatments have a number of advantages including increased convenience, ease of 
administration and fewer clinic appointments, resulting in a reduced impact on quality of life [23]. Other single agents and a range of 
chemotherapy combinations may also be administered depending on the clinical scenario. Whilst further discussion of cytotoxic 
regimens is outside the scope of this thesis, the National Comprehensive Cancer Network Guidelines provide synthesised evidence of 
all available therapies and indications for initiation [18]. There is no optimal chemotherapy regimen, with treatment choice 
dependant on factors such as treatment efficacy and toxicity, prior treatment, comorbid conditions and performance status [21]. 
Chemotherapy agents, whether used individually or in combination, can cause significant side effects. Nausea and vomiting are 
common across therapies despite improvements in anti-emetic therapy [24]. Other common side effects include fatigue, hair loss, 
neutropenia, cardiac toxicity and neuropathy [25]. Some cytotoxic agents also possess risks specific to that class of drug. For example, 
the use of taxanes may result in peripheral oedema, impacting on mobility [25].      
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Anti-HER2-targeted therapy 
Prior to the introduction of new therapies, women with an HER2 positive tumour (HER2+) traditionally had a poor prognosis [26]. 
These women are now offered anti-HER2-targeted treatments, irrespective of hormone receptor status. The National Comprehensive 
Cancer Network Guidelines recommend two agents, pertuzumab plus trastuzumab, as the preferred first-line treatment [18]. These 
therapies bind to the HER2 protein, inhibiting proliferation of tumour cells. Anti-HER2-targeted therapy may be administered in 
combination with endocrine therapy or chemotherapy, or alone. The use of pertuzumab with trastuzumab can result in mild side 
effects such as diarrhoea, neutropenia, skin and nail infections, and infusion reactions. A more significant risk, albeit rare, is damage 
to the heart and subsequent cardiac dysfunction [27].  
Bone-targeted therapy 
Bone metastasis occurs in approximately 70% of women with metastatic breast cancer [28]. This can lead to skeletal-related events 
such as pathological fracture, causing significant morbidity and impacting on quality of life.  The use of bisphosphonates and 
denosumab can reduce and delay the incidence of skeletal-related events [29]. Whilst neither agent has an impact on overall survival, 
denosumab has demonstrated superiority over the commonly used bisphosphonate zoledronic acid [30, 31]. These therapies can be 
administered orally or intravenously and may be used with or without other treatment [11]. As there is a continuing risk of skeletal-
related events, treatment is ongoing unless tolerability or compliance issues arise [31]. 
Whilst generally well-tolerated, oral bisphosphonates can cause gastrointestinal issues. Intravenous administration is associated with 
side effects such as flu-like symptoms and bone pain after infusion [32]. Individuals taking denosumab may experience 
breathlessness, diarrhoea or bone, joint or muscle pain. More severe risks of both these therapies include osteonecrosis of the jaw 
and renal toxicity [32].  
Surgery 
There is no established benefit to removing the primary tumour in metastatic breast cancer so surgical resection is not routinely used 
[11]. However, surgery may be considered after initial systemic therapies for the palliation of symptoms of the breast tumour, such as 
skin ulceration, bleeding and pain [33]. Surgery also has a role in the localised control of the metastases site and may be indicated in 
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scenarios such as brain metastases or pleural effusion [18]. In the event of a fracture in a weight-bearing bone, or where one is 
inevitable, surgery may be used to stabilise the bone [25]. As with all treatments, surgery carries inherent risks. Individuals may 
experience pain, infection, seroma or lymphoedema, depending on the surgical site. 
Radiation therapy 
As an alternative to surgery, radiation therapy may be adopted to manage symptoms at the site of the primary tumour or distant 
metastases [18]. For metastatic bone pain, palliative radiotherapy is the most effective approach, with approximately two-thirds 
experiencing complete pain relief [34]. Common side effects of radiation include reddening and soreness of the skin, discomfort and 
swelling, fatigue and nausea.Practice guidelines provide evidence-based recommendations for medical management using the various 
treatment strategies. However, with chronic conditions such as hypertension, depression, arthritis and diabetes common in an older 
metastatic population [21], the applicability of guidelines to individuals with multiple comorbidities is often questionable. Clinicians 
creating treatments plans for this complex and heterogeneous population are required to identify and consider all other comorbid 
conditions. This makes treatment decisions challenging, often resulting in guidelines that are modified or disregarded for these 
women [21].   
Treatment and outlook for women living with metastatic breast cancer are varied, making it difficult to generalise about those living 
with this disease. There are currently many available treatment options including endocrine therapy, chemotherapy, targeted 
therapies, surgery and radiation, and these are constantly evolving. Over the course of an individual’s disease, treatment will typically 
involve several of these therapies alone or in combination. 
Symptom burden 
In addition to treatment-related side-effects, women with metastatic breast cancer also present with a variety of symptoms caused 
directly or indirectly by the metastatic lesion itself (Table 1) [5, 35, 36]. Due to the varying treatment approaches and heterogeneous 
nature of the disease, some women with metastatic breast cancer experience high levels of symptom burden whereas others are not 
significantly debilitated and are able to continue in their usual roles [37]. As a result of ongoing treatment and adjustments, recent 
research suggests that this population actually experience oscillating cycles of decline and reprieve [38]. 
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Table 1. Common disease-related symptoms of metastatic breast cancer  
Metastasis site  Prevalence of metastatic site Common side effects 
Bone 61% 
Bone pain,  fatigue, fracture, nerve 
entrapment, hypercalcaemia  
Liver 49% 
Discomfort at site of liver, nausea, loss of 
appetite, ascites, jaundice  
Lung 41% 
Cough, breathlessness, pleural effusion, 
pain, hemoptysis  
Brain 28% 
Headaches, confusion, nausea, memory 
problems, neurological issues, poor balance, 
weakness, seizure, pain  
 
As metastatic breast cancer diagnosis is often viewed as a life-altering event, it can have a significant impact on psychological well-
being [39]. A range of existential issues can arise such as feelings of hopelessness, uncertainty, fear of death, and loss of identity and 
independence [40]. Other evidence of poor psychological well-being may be signs of depression or anxiety [41]. Estimates of 
depression in this population range from 20-50%, although there is a much lower prevalence of major depressive disorders [35]. 
Psychological support, anxiolytics and antidepressants may be offered for treatment of depressive symptoms.        
The most common symptoms that women with metastatic disease endure are pain and fatigue [42]. Pain may present as a symptom 
of bone or visceral metastasis or may be associated with treatments such as surgery or endocrine therapy. There are several 
intervention options for the treatment of pain. For neuropathic pain, analgesics such as antidepressants and anticonvulsants are often 
prescribed in combination with opioids, whilst some women gain relief from topical anaesthetics [41]. Glucocorticoids may also be 
indicated if the pain is of an inflammatory nature or a result of nerve compression. In addition to the role of bisphosphonates, 
denosumab and radiation therapy for bone pain, other treatment options include glucocorticoids, opioid or non-opioid analgesics or 
systemic radiopharmaceuticals [41].  
Cancer-related fatigue is a persistent and debilitating symptom affecting 70% to 100% of those with cancer [43]. Fatigue is 
multidimensional, with factors contributing to its manifestation from the metastatic site itself, treatments, physical deconditioning 
and other comorbid conditions [42, 44]. Depressive symptoms, as well as inadequate sleep, pain and decreased cognitive function, 
are also associated with fatigue [42]. Fatigue has a profound effect physically, emotionally and mentally, often interfering with 
activities of daily living and causing a considerable decline in overall quality of life [45]. Some contributing factors to fatigue are more 
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amenable to intervention than others. Nonpharmacological management strategies include energy conservation, distraction, physical 
activity and psychosocial interventions such as cognitive behavioural therapy [46]. These have been examined primarily in early stage 
cancer but may also have a role in metastatic disease.   
Whilst most symptoms and side effects of metastatic breast cancer are well-described in the literature, the level of physical 
deconditioning in this population remains unclear. One study investigating functional decline in this population reported that 92% of 
women possessed at least one physical impairment and 47% had deficits in muscle strength [47]. Another study found that women 
with metastatic breast cancer undergoing chemotherapy had marked impairment in cardiopulmonary function, with peak oxygen 
consumption 33% lower than healthy sedentary women [48]. Whilst deficits in function have been identified, the physical capabilities 
of this heterogeneous population are not well understood, particularly with respect to aerobic fitness and habitual physical activity 
level. These gaps led to the development of a cross-sectional study to identify physical function deficits of women living with 
metastatic breast cancer, described in Chapter 2. 
Although many women with metastatic breast cancer experience debilitating side-effects, these are often overlooked as healthcare 
providers focus on treatment and improving survival [49]. While positive about medical care in general, women are dissatisfied with 
this approach and want more focus placed on ensuring good quality of life [49]. In the absence of supportive care, women engage in a 
number of strategies to help them live well with their disease [50]. Being physically active is a popular approach, with one cross-
sectional study reporting that more than 50% of the population exercised at least twice a week [50]. Despite being a commonly 
adopted strategy, the role of physical activity and exercise for people with metastatic disease has not been well-established and will 
be explored in Chapter 4.   
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Physical activity and exercise interventions in women with early breast cancer  
A wide variety of treatment strategies have been adopted to improve well-being in women with early breast cancer, including 
pharmacological, psychosocial and mind-body interventions [51, 52]. Physical activity and exercise are also popular supportive care 
choices. Whilst physical activity encompasses any movement carried out by the skeletal muscles above resting levels, exercise forms a 
subcategory of physical activity [53]. Exercise is activity that is planned and structured with the aim of improving or maintaining 
physical fitness [53]. There is a large body of evidence describing the role of exercise in women with early stage breast cancer. 
Systematic reviews summarising the evidence are presented in Table 3. Whilst some reviews focused on a particular symptom, 
treatment or exercise modality and others reported more broadly, all show a clear benefit from an exercise intervention [54-68]. 
The effects of exercise on patient-reported outcomes such as QOL and fatigue were favourable [54-57, 59-62]. As these systematic 
reviews examined mixed training modalities, it is unclear whether the benefit is attributable to resistance or aerobic training alone or 
in combination. Irrespective, exercise is accepted as a safe and effective therapy for managing fatigue and other disease-related 
symptoms in women with early breast cancer.  
The systematic reviews consistently reported improvements in aerobic fitness and muscular strength with exercise training [54, 56-
58, 60-62]. Upper body strength and function are important in breast cancer post-surgery for restoring the ability to perform activities 
of daily living and preventing disuse atrophy and associated impairments. One of the most recent reviews examining exercise and 
lymphoedema demonstrated that resistance and aerobic training are safe and effective and do not increase the risk or severity of 
lymphoedema [57].   
Most of the systematic reviews on exercise and early breast cancer noted limitations such as a small number of studies, poor quality 
methodology and reporting of results, and short length of follow-up [54, 57, 58, 61, 69]. Despite these limitations, these reviews 
support the prescription of exercise for improving physiological, psychological and functional variables in early breast cancer patients. 
Given the benefits of exercise, the American College of Sports Medicine has recommended that cancer survivors follow the 2008 
Physical Activity Guidelines for Americans [70]. This advice encourages survivors to engage, where possible, in 150 minutes per week 
of moderate-to-vigorous intensity exercise and include aerobic and resistance components [70]. It was noted in these Guidelines that 
prescription should be individualised and adapted to account for the limitations of each individual [70].  
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Table 3. Systematic reviews of exercise interventions in early breast cancer 
Systematic review Review 
period 
Included 
cancers 
Exercise 
modality 
Study 
design 
Quality Assessment Procedure # studies 
included 
Outcomes 
Effects of supervised 
exercise on cancer-
related fatigue in breast 
cancer survivors: a 
systematic review and 
meta-analysis [59] 
2001-
2013 
Breast  Aerobic 
training ± 
resistance 
training 
RCTs  Pedro scale [71] 9 
PROs 
↓ fatigue  
↑ functional and physical 
well-being 
↔ social and emotional 
well-being 
↔ depression 
Tai chi 
chuan exercise for 
patients with breast 
cancer: a systematic 
review and meta-
analysis [63] 
 
2004-
2013 
Breast  Tai Chi 
Chuan 
RCTs  Cochrane Risk of Bias Assessment 
Tool [72] 
9 
PROs 
↔ pain 
↑ upper body strength 
↑ flexibility   
↔ in physical, emotional or 
social  well-being 
↔ QOL 
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Systematic review Review 
period 
Included 
cancers 
Exercise 
modality 
Study 
design 
Quality Assessment Procedure # studies 
included 
Outcomes 
Safety and efficacy of 
progressive resistance 
training in breast 
cancer: a systematic 
review and meta-
analysis [57] 
2006-
2013 
Breast  Resistance 
training 
RCTs  Quality checklist designed based on 
established criteria [73] 
15 
Physical Function 
↓ risk of lymphoedema 
incidence/exacerbation 
↑ upper and lower body 
strength  
PROs 
↑ QOL 
Weight training is not 
harmful for women 
with breast cancer-
related lymphoedema: 
a systematic review 
[60] 
2001-
2012  
Breast  Resistance 
training 
RCTs  Pedro scale [71] 8 
Physical Function 
↔ risk or severity of 
lymphoedema  
↑ upper and lower body 
strength  
PROs 
↑ QOL 
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Systematic review Review 
period 
Included 
cancers 
Exercise 
modality 
Study 
design 
Quality Assessment Procedure # studies 
included 
Outcomes 
Twenty-five years of 
research on the effects 
of exercise training in 
breast cancer survivors: 
A systematic review of 
the literature [54] 
1988-
2013 
Breast  Aerobic ± 
resistance 
training 
RCTs, 
UCTs 
Not described 51 
(37 RCTs) 
 
Physical Function 
↑ cardiorespiratory function 
↑ upper and lower body 
strength  
PROs 
↑ QOL  
↓  depression 
Progressive resistance 
training in breast 
cancer: a systematic 
review of clinical trials 
[56] 
1995-
2007 
Breast  Resistance 
training ± 
other 
modalities 
RCTs, 
CCTs,  
UCTs 
Delphi List [74] 10  
(5 RCTs) 
Physical Function 
↑ upper and lower body 
strength  
↑ aerobic fitness 
PROs 
↑ QOL, depression, anxiety 
and self-esteem 
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Systematic review Review 
period 
Included 
cancers 
Exercise 
modality 
Study 
design 
Quality Assessment Procedure # studies 
included 
Outcomes 
An update of controlled 
physical activity trials 
in cancer survivors: 
a systematic review and 
meta-analysis [61] 
2005-
2009 
Mix 
(breast 
83%) 
Aerobic 
and/or 
non-
aerobic 
RCTs, 
CCTs 
10 internal validity characteristics 
[75] 
82 
(74 RCTs) 
Physical Function 
↑ aerobic fitness 
↑ upper and lower body 
strength  
PROs 
↑ QOL 
↔ social or emotional well-
being  
↔ depression 
↓ fatigue 
↔ pain  
Resistance exercise and 
secondary 
lymphoedema in breast 
cancer survivors –a 
systematic review [66] 
1966-
2015 
Breast Resistance RCTs Downs and Black risk of bias 
assessment [76] 
9 
Physical Function 
↔ risk or severity of 
lymphoedema 
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Systematic review Review 
period 
Included 
cancers 
Exercise 
modality 
Study 
design 
Quality Assessment Procedure # studies 
included 
Outcomes 
Exercise and cancer 
rehabilitation: A 
systematic review [62] 
1997-
2009 
Mix 
(breast 
80%) 
Aerobic 
and/or 
resistance 
training ± 
flexibility 
training 
RCTs, 
CCTs,  
UCTs 
Stevinson method [77] 10 
(4 RCTs) 
Physical Function 
↑ physical function 
↑ upper and lower body 
strength 
PROs 
↑ QOL 
↓ fatigue 
Resistance Training in 
Cancer Survivors: A 
Systematic Review [58] 
1993-
2008 
Mix 
(breast 
83%) 
Resistance 
training ± 
other 
modalities 
RCTs, 
CCTs,  
UCTs 
Pedro scale [71] 24 
(10 RCTs) 
Physical Function 
↑ cardiopulmonary function 
↑ muscle strength and 
endurance 
 
Effects of exercise on 
quality of life in women 
living with breast 
cancer: a systematic 
review [55] 
2001-
2006 
Breast Aerobic, 
resistance, 
dance, tai 
chi 
RCTs  van Tulder criteria [78] 9 
PROs 
↑ QOL 
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Systematic review Review 
period 
Included 
cancers 
Exercise 
modality 
Study 
design 
Quality Assessment Procedure # studies 
included 
Outcomes 
Yoga for improving 
health-related quality 
of life, mental health 
and cancer-related 
symptoms in women 
diagnosed with breast 
cancer [65] 
2007-
2015 
Breast Yoga RCTs Cochrane Risk of Bias Assessment 
Tool [72] 
23 
PROs 
↑ QOL 
↔ depression and anxiety  
↓ fatigue 
 
Effects of exercise on 
breast cancer patients 
and survivors: a 
systematic review and 
meta-analysis [64] 
1989-
2006 
Breast Aerobic 
and/or 
resistance 
RCTs Author-developed predefined 
criteria  
14 
Physical Function 
↑ aerobic fitness 
PROs 
↑ QOL 
↑physical function and well-
being 
↓ fatigue 
The impact of exercise 
during adjuvant 
radiotherapy for breast 
cancer on fatigue and 
quality of life: a 
systematic review and 
meta-analysis [67]  
1966-
2015 
Breast Aerobic, 
resistance, 
yoga, 
qigong, tai 
chi, pilates 
RCTs Pedro scale [71] 9 
PROs 
↔  QOL 
↓ fatigue 
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Systematic review Review 
period 
Included 
cancers 
Exercise 
modality 
Study 
design 
Quality Assessment Procedure # studies 
included 
Outcomes 
Breast-cancer related 
lymphoedema and 
resistance exercise: a 
systematic review [68] 
2006-
2015 
Breast Resistance RCTs Pedro scale [71] 6 
Physical Function 
↑ upper and lower body 
strength  
↔ risk or severity of 
lymphoedema 
RCT: Randomised controlled trial, CCT: Controlled clinical trial, UCT: Uncontrolled clinical trial, QOL: Quality of life
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Exercise training in people with metastatic cancer 
The role of exercise in breast cancer has traditionally focused on women with early stage disease. Women 
with metastatic disease are typically excluded because of fear of pathological bone fracture or other skeletal 
complications [79, 80]. In cases where they have been included, subgroup analysis is usually not possible due 
to such small numbers [42]. This exclusion is not limited to metastatic breast cancer and is also evident in 
metastatic disease from other primary tumours.  
A summary of exercise interventions for metastatic cancer from all primary sites is shown in Table 4. These 
studies include either a population that was exclusively metastatic [79, 81-93] or if early stage patients were 
also included, an analysis of metastatic patients presented separately [94]. Only 12 studies described in 15 
publications were identified, illustrating the preliminary nature of this work. These studies were 
predominantly a mix of randomised controlled trials [82, 89, 92-94] and uncontrolled trials [79, 81, 86-88]. 
Three case reports [83-85] were also presented, although their limited level of evidence was acknowledged, 
due to the limited literature in the area. The studies comprised a variety of populations, with four conducted 
solely in women with metastatic breast cancer [82, 85, 86, 92] and the remainder in other or mixed 
metastatic populations [79, 81, 83, 84, 87-91, 93, 94].  
The studies varied in terms of sample size, methods and design (Table 4). Sample sizes were generally small, 
ranging from single case studies [83-85] to a larger cohort of 101 [92], with a median sample size of 32. The 
quality of these studies was assessed using the PEDro scale (Table 5), which consists of ten items to give a 
score out of ten [71]. Two items relating to blinding of participants and trainers were not rated as this is 
impractical in exercise interventions [58, 67]. Eight criteria were therefore assessed resulting in scores from 
0 to 8, with studies scoring ≥4 out of 8 considered high quality [67]. As 6 out of the 12 studies were case 
reports or uncontrolled trials, the median quality score across studies was low (2 out of 8). Furthermore, as 
these case reports or uncontrolled trials did not have a control group, criteria such as randomisation, 
concealment of allocation and blinding of assessors could not be applied. Five RCTs were considered high 
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quality [81, 89, 92-94], with only one fulfilling all quality criteria [94]. One RCT scored 7 out of 8 [81], failing 
to adopt blinded assessment of outcome measures. The absence of blinded assessors was also evident in 
three additional RCTs [82, 89, 93]. Whilst blinding of this nature is technically possible with an exercise 
intervention, it may prove to be a logistical challenge due to the additional expertise and personnel required. 
There were also other common deficiencies across the six RCTs; three failed to report using a valid method 
of allocation concealment [82, 89, 92], three had >15% loss to follow-up [82, 92, 93] and four did not analyse 
using intention to treat [82, 89, 92, 93]. However, all of the RCTs demonstrated similarity between groups at 
baseline and appropriate between-groups statistical testing [81, 82, 89, 92-94]. The methods applied by the 
two highest quality studies [81, 94] should provide guidance for the design of future interventions.      
The exercise interventions implemented across studies were heterogeneous (Table 4).  Most studies 
included resistance training [81, 93, 94], aerobic training [84, 85] or a combination of both [83, 87]. 
Resistance training was prescribed two to three times per week in five studies [38, 50, 51, 40, 44], with 
program duration ranging from 6 [87] to 13 weeks [83]. The majority of these programs were conducted at a 
moderate intensity [81, 83, 87, 93, 94] in a gym or clinical facility [81, 83, 87, 94]. The three aerobic only 
interventions ranged from two sessions per week [84] to as many desired by the participant to obtain 150 
minutes per week of moderate-intensity activity [92]. The duration of these aerobic programs was 6 weeks 
[84], 16 weeks [92] and 12 months [85]. The remaining trials used less traditional forms of activity such as 
yoga or repetitive motion exercises [82, 86], while others did not specify details of the intervention [88, 89].  
As metastatic breast cancer and its treatments can have a negative impact on physical capacity [42, 49], 
maintenance and improvement of physical function play an important role in prolonging independence and 
regaining quality of life [95]. Of the five high-quality studies, three incorporated resistance training [81, 93, 
94]. Two of these evaluated physical performance with reported improvements observed in muscular 
strength and other functional outcomes such as walking capacity [81, 94]. Both studies were carried out in a 
predominantly metastatic prostate population, with the inclusion of only three women (15%) who presented 
with metastatic breast [81]. Whilst these findings are promising, given the variations in treatment approach 
19 
 
and clinical course of the two metastatic diseases, the generalisability of these findings to women living with 
metastatic breast cancer is unclear. Most notably, of the studies that assessed safety, there were no adverse 
events related to the interventions [79, 81, 84, 85, 87, 92, 93]. 
All of the trials presented in Table 4 evaluated patient-reported outcomes (PROs), with four high-quality 
studies specifically examining the effect of the intervention on fatigue [81, 92-94]. Three of these reported 
either a significant improvement or a trend towards improvement in fatigue, with all three adopting 
resistance training alone or in combination with an aerobic component [81, 93, 94]. The only study with 
equivocal fatigue outcomes comprised an aerobic only training program [92].  However, higher than 
anticipated attrition in this study limited power for between-group comparisons [92]. Overall, findings from 
these preliminary studies suggest that exercise may have the potential for addressing cancer-related fatigue.  
The majority of exercise interventions delivered to metastatic populations have prescribed training at a 
moderate intensity [81, 83-85, 92-94], with only a couple targeted to lower intensities [82, 87]. A moderate 
workload appears achievable for at least some women living with metastatic breast cancer but there is a 
paucity of evidence for exercise at higher intensities. Even though high-intensity training may be suitable for 
part of the population, safety and feasibility may be compromised in those with reduced physical function. 
Deficits in muscle strength [47] and aerobic fitness [48] have been identified in women undergoing 
chemotherapy, although physical capabilities more broadly are relatively unknown. To address this gap, a 
study was designed and conducted to describe the deconditioning and physical capacity of this 
heterogeneous population (Chapter 2). The findings from this cross-sectional study were then used to 
develop and conduct an appropriately pitched physical activity program (Chapter 4).  
The design of an intervention with consideration for physical activity interests and preferences may 
encourage participation and enhance adherence. Eighty-four percent of 50 palliative cancer patients with an 
estimated life expectancy of between 3 and 12 months reported a preference to perform physical activity in 
the home [96]. It is currently unknown whether women living in the community with metastatic breast 
cancer share similar preferences to palliative care patients. The majority of exercise interventions for 
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metastatic populations have been conducted in a gymnasium or clinic environment [81, 83-87, 89, 94, 97], 
allowing access to specialised equipment and trainers. However, delivery of exercise in this setting may 
create barriers to participation and limit translation into the community. Physical activity preferences of 
women living with metastatic breast cancer are explored in Chapter 3 through structured interviews to assist 
in the development of the physical activity intervention.  
The small number of studies investigating the role of exercise in metastatic cancer and limitations such as 
small diverse samples, uncontrolled trials and heterogeneous interventions, presents a challenge for 
generalising these findings and determining applicability to this population. Despite this, preliminary findings 
suggest that exercise may have a positive impact on physical and psychosocial well-being in individuals living 
with metastatic disease. Chapter 4 evaluates the safety, feasibility and efficacy of a physical activity 
intervention based on the preferences and physical capacity of women living with metastatic breast cancer, 
obtained for Chapters 2 and 3.
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Table 4. Exercise interventions in metastatic cancer 
Article Participants Study Design Intervention Outcomes Measures Results Quality Score^ 
The effect of a 
physical exercise 
program in 
palliative care: a 
phase II study  
Oldervoll, 2006 [87] 
n= 47 
Primary cancer: 
GI, breast, 
genitourinary, 
prostate, ovary, 
kidney, lung, 
other 
Met site: 
visceral and 
bone 
Current 
treatment: 
chemotherapy 
or hormone 
therapy 
Uncontrolled 
trial 
Duration: 6 
weeks, 2x week  
Program: Circuit 
training 
(resistance and 
aerobic) of 50m 
duration 
Intensity: low 
Location: clinic  
Safety and tolerability  
Adverse events 
Adherence 
Physical function 
6m walk 
Timed sit-to-stand 
Functional reach 
PROs 
European Organization for 
Research and Treatment of Cancer 
Quality of Life Questionnaire-C30 
(EORTC QLQ-C30) 
Fatigue Questionnaire (FQ) 
Safety and tolerability 
No adverse events 
Adherence of 88% 
Physical function 
Significant improvement in walking 
distance and timed sit-to-stand 
PROs 
Significant improvement in 
emotional, role and social 
functioning 
Significant improvement in dyspnoea 
Improvements in  fatigue 
approached statistical significance 
1/8 
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Article Participants Study Design Intervention Outcomes Measures Results Quality Score^ 
Safety and efficacy 
of resistance 
exercise in prostate 
cancer patients 
with bone 
metastases  
Cormie, 2013 [81] 
 
Functional benefits 
are sustained after 
a program of 
supervised 
resistance exercise 
in cancer patients 
with bone  
metastases: 
longitudinal results 
of a pilot study  
Cormie, 2014 [79] 
 
n=30 
Primary cancer: 
prostate  
Met site: bone 
Current 
treatment: not 
specified 
Randomised 
controlled 
trial 
Duration: 12 
weeks, 2x week  
Program: 
resistance training 
of ~60m duration 
+ walking 
Intensity: 
moderate 
Location: clinic 
Safety and tolerability  
Adverse events 
Bone pain 
Attendance 
Compliance 
Physical function 
1RM leg extension 
 400m and 6m walk 
Timed up and go 
Sensory organisation test 
Body composition 
Lean body mass 
BMD 
PROs 
Medical Outcomes Study 36-Item 
Short-Form Health Survey (SF-36) 
Brief Symptom Inventory-18 (BSI) 
Multidimensional Fatigue 
Symptom Inventory-Short Form 
(MFSI-SF) 
Safety and tolerability 
No adverse events 
No significant changes in bone pain 
Attendance of 85% 
Compliance of 89% 
Physical function 
Significant improvements in muscle 
strength, aerobic capacity and 
ambulation 
Trend towards improvement in 
timed up and go and balance 
Body composition 
Significant increase in whole body 
lean mass and BMD at the hip 
PROs 
Significant increase in social 
functioning 
Trend towards improvement in 
physical functioning, role-physical 
and physical health 
Improvements in cancer-related 
fatigue approached statistical 
significance 
7/8* 
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Article Participants Study Design Intervention Outcomes Measures Results Quality Score^ 
The effect of seated 
exercise on fatigue 
and quality of life in 
women with 
advanced 
breast cancer  
Headley, 2004 [82] 
 
n=38 
Primary cancer: 
breast  
Met site: not 
specified 
Current 
treatment: 
chemotherapy 
Randomised 
controlled 
trial 
Duration: 12 
weeks, 3x week  
Program: seated 
exercise program 
of repetitive 
motion exercises 
of 30m duration 
Control: usual 
care 
Intensity: low-
moderate 
Location: home 
PROs 
Functional Assessment of Chronic 
Illness – Fatigue (FACIT-F) 
 
PROs 
Physical and functional well-being 
decreased in both groups but the 
intervention group experienced 
significantly less decrease 
Fatigue increased in both groups but 
the intervention group experienced 
significantly less increase 
3/8 
Physical training 
during intrahepatic 
chemotherapy 
Kelm, 2003 [83] 
n=1 
Primary cancer: 
rectal 
Met site: 
visceral 
Current 
treatment: 
chemotherapy 
Case study Duration: 13 
weeks, 2x week  
Program: 
resistance and 
aerobic training 
Intensity: 
moderate 
Location: clinic 
Physical function 
Submaximal treadmill test 
FEV1 and FVC 
PROs 
Gastrointestinal Quality of Life 
Index 
 
Physical function 
Decrease in heart rate and lactate 
concentration 
Improved lung function 
PROs 
Improvement in quality of life  
0/8 
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Article Participants Study Design Intervention Outcomes Measures Results Quality Score^ 
Aerobic exercise as 
additive palliative 
treatment for a 
patient with 
advanced 
hepatocellular 
cancer  
Crevanna, 2003 
[84] 
n=1 
Primary cancer: 
liver 
Met site: 
visceral 
Current 
treatment: not 
specified 
Case study Duration: 6 
weeks, 2x week  
Program: cycle 
ergometry of 35m 
duration 
Intensity: 
moderate 
Location: clinic 
Safety and tolerability  
Adverse events 
Physical function 
VO2max 
Peak work capacity 
PROs 
Medical Outcomes Study 36-Item 
Short-Form Health Survey (SF-36) 
 
Safety and tolerability 
No adverse events 
Physical function 
Increase in VO2max and peak work 
capacity 
PROs 
Improvement in physical functioning, 
mental health, pain, vitality and 
general health perception  
0/8 
Aerobic exercise for 
a patient suffering 
from metastatic 
bone disease  
Crevanna, 2003 
[85] 
 
n=1 
Primary cancer: 
breast  
Met site: 
visceral and 
bone 
Current 
treatment: 
chemotherapy 
+ radiotherapy 
Case study Duration: 52 
weeks, 3x week  
Program: cycle 
ergometry of 50m 
duration 
Intensity: 
moderate 
Location: clinic 
Safety and tolerability  
Adverse events 
Physical function 
VO2max 
6m walk 
PROs 
Grimby’s questionnaire 
Medical Outcomes Study 36-Item 
Short-Form Health Survey (SF-36) 
 
Safety and tolerability 
No adverse events 
Physical function 
Increase in VO2max and 6m walk 
PROs 
Improvement in physical functioning, 
mental health, role function, social 
function, pain and vitality  
0/8 
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Article Participants Study Design Intervention Outcomes Measures Results Quality Score^ 
Yoga for women 
with metastatic 
breast cancer: 
results from a pilot 
study  
Carson, 2007 [86] 
n= 18 
Primary cancer: 
breast 
Met site: not 
specified 
Current 
treatment: 
chemotherapy 
or not specified 
 
Uncontrolled 
trial 
Duration: 8 
weeks, 1x formal 
session per week 
+ 10min per day  
Program: ‘Yoga of 
Awareness’ 
program of 120m 
duration  gentle 
stretches, 
meditation and 
discussion 
Intensity: not 
reported 
Location: clinic 
(10m/day at 
home) 
PROs 
Daily symptom diary 
 
PROs 
Significant improvement in daily 
invigoration and acceptance 
Trend for improvement in pain and 
relaxation 
0/8 
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Article Participants Study Design Intervention Outcomes Measures Results Quality Score^ 
An exercise 
intervention for 
advanced cancer 
patients  
experiencing 
fatigue: a pilot 
study  
Porock, 2000 [88] 
n=9 
Primary cancer: 
bowel, 
pancreas, 
melanoma, 
breast, oral  
Met site: not 
specified 
Current 
treatment: 
chemotherapy 
or radiotherapy 
or none 
Uncontrolled 
trial 
Duration: 28 days, 
several sessions 
per day  
Program: not 
specified – 
reported as ‘a 
range of activities’ 
Intensity: not 
reported 
Location: home 
PROs 
Multidimensional Fatigue 
Inventory (MFI) 
Symptom Distress Scale (SDS) 
Hospital Anxiety and Depression 
Scale (HADS) 
Quality of Life Scale (QOL Scale) 
PROs 
No change in fatigue 
Trend towards decreasing anxiety 
Improvement in QOL  
1/8 
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Article Participants Study Design Intervention Outcomes Measures Results Quality Score^ 
Impacting QOL for 
patients with 
advanced cancer 
with a structured 
multidisciplinary 
intervention: a 
randomized 
controlled trial  
Rummans, 2006 
[89] 
Will improvement 
in quality of life 
(QOL) impact 
fatigue in patients 
receiving radiation 
therapy for 
advanced cancer?  
Brown, 2006 [90] 
Improving the QOL 
of geriatric cancer 
patients with a 
structured  
multidisciplinary 
intervention: a 
randomized 
controlled Trial 
Lapid, 2007 [91] 
n=49 
Primary cancer: 
GI, lung, 
head/neck, 
brain, ovary, 
other 
Met site: not 
specified 
Current 
treatment: 
radiotherapy 
Randomised 
controlled 
trial 
Duration: 3 
weeks, total of 8 
sessions 
Program: 
conditioning, 
education and 
discussion of 90m 
duration 
Control: usual 
care 
Intensity: not 
reported 
Location: clinic 
PROs 
The Spitzer QOL Uniscale 
Linear Analog Scales of 
Assessment (LASAs)  
Symptom Distress Scale (SDS) 
Profile of Mood States (POMS) 
Functional Assessment of Chronic 
Illness Therapy–Spiritual Well-
Being (FACIT-SWB) 
PROs 
QOL significantly decreased in 
control group but was maintained in 
intervention group  
5/8* 
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Article Participants Study Design Intervention Outcomes Measures Results Quality Score^ 
Resistance exercise 
in men receiving 
androgen 
deprivation therapy 
for prostate cancer  
Segal, 2003 [94] 
n=60 (being 
treated with 
palliative 
intent) 
Primary cancer: 
prostate 
Met site: not 
specified 
Current 
treatment: 
androgen 
deprivation 
therapy 
Randomised 
controlled 
trial 
Duration: 12 
weeks, 3x week  
Program: 
resistance training 
Control: waitlist 
Intensity: 
moderate 
Location: gym 
Physical function 
Chest press load test 
Leg press load test 
Body composition 
Skinfolds 
BMI 
Waist circumference 
PROs 
Functional Assessment of Cancer 
Therapy-Fatigue (FACIT-F) 
Functional Assessment of Cancer 
Therapy-Prostate (FACIT-P) 
Physical function 
Significant increase in upper and 
lower body strength  
Body composition 
No difference 
PROs 
Improvements in  fatigue 
approached statistical significance 
8/8* 
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Article Participants Study Design Intervention Outcomes Measures Results Quality Score^ 
Randomized trial of 
a physical activity 
intervention in 
women with 
metastatic breast 
cancer  
Ligibel, 2016 [92]  
 
n= 101 
Primary cancer: 
breast 
Met site: 
visceral and 
bone 
Current 
treatment: 
chemotherapy 
or radiotherapy 
or targeted 
therapy or 
none 
Randomised 
controlled 
trial 
Duration: 16 
weeks, total of 
150min/wk  
Program: aerobic 
training  
Control: waitlist 
Intensity: 
moderate 
Location: gym and 
home 
Safety and tolerability  
Adverse events 
Attrition 
Physical function 
Bruce Ramp Treadmill 
PROs 
European Organization for 
Research and Treatment of Cancer 
Quality of Life Questionnaire-C30 
(EORTC QLQ-C30) 
Functional Assessment of Chronic 
Illness – Fatigue (FACIT-F) 
Safety and tolerability 
No adverse events 
Attrition rate of 30%  
Physical function 
Non-significant improvement in test 
duration 
PROs 
Non-significant improvement in 
global QOL 
No change in  fatigue  
5/8* 
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Article Participants Study Design Intervention Outcomes Measures Results Quality Score^ 
A home-based 
exercise program 
to improve 
function, fatigue, 
and sleep quality in 
patients with stage 
IV lung and 
colorectal cancer: a 
randomized 
controlled trial 
Cheville, 2003 [93] 
n= 65 
Primary cancer: 
lung, colorectal 
Met site: not 
specified 
Current 
treatment: 
chemotherapy  
or radiotherapy  
Randomised 
controlled 
trial 
Duration: 8 
weeks, 2 x week  
Program: 
resistance training 
+ walking 
Control: waitlist 
Intensity: 
moderate 
Location: home 
Safety and tolerability  
Adverse events 
Adherence 
PROs 
AM-PAC CAT 
AM-PAC Mobility 
Functional Assessment of Cancer 
Therapy– General (FACT-G) 
Functional Assessment of Chronic 
Illness – Fatigue (FACIT-F) 
Pain rating 
Sleep quality rating 
Safety and tolerability 
No adverse events 
Adherence of 77% 
PROs 
Significant improvements in 
mobility, fatigue and sleep quality 
 
5/8* 
^Quality score determined by the PEDro scale [71] *Considered a high-quality study based on PEDro score ≥4  
 
 
 
 
  
31 
 
Table 5. Methodological quality of included exercise interventions in metastatic cancer using the PEDro scale 
Article Study Design 1 2 3 4 5 6 7 8 Total 
Oldervoll, 2006 [87] UCT - - - - - - - + 1/8 
Cormie, 2013 [81] 
Cormie, 2014 [79] 
RCT + + + - + + + + 7/8* 
Headley, 2004 [82] RCT + - + - - - + - 3/8 
Kelm, 2003 [83] CS - - - - - - - - 0/8 
Crevanna, 2003 [84] CS - - - - - - - - 0/8 
Crevanna, 2003 [85] CS - - - - - - - - 0/8 
Carson, 2007 [86] UCT - - - - - - - - 0/8 
Porock, 2000 [88] UCT - - - + - - - - 1/8 
Rummans, 2006 [89] 
Brown, 2006[90] 
Lapid, 2007 [91] 
RCT + - + - + - + + 5/8* 
Segal, 2003 [94] RCT + + + + + + + + 8/8* 
Ligibel, 2016 [92]  RCT + - + + - - + + 5/8* 
Cheville, 2013 [93] RCT + + + - - - + + 5/8* 
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1: use of randomisation; 2: allocation was concealed; 3: similarity of groups at baseline regarding the most important prognostic factors; 4: blinding of assessors; 5: 
obtainment of key outcome measures from more than 85% of the subjects; 6: use of an intention to treat analysis; 7: reporting of results of between-group 
statistical comparisons of at least one key outcome measure; 8: reporting of point estimates and variability. 
 
*Considered a high-quality study based on PEDro score ≥4 +: met criteria, -: did not meet criteria, RCT: Randomised controlled trial, CCT: Controlled clinical trial, 
UCT: Uncontrolled clinical trial, CS: Case Study
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Monitoring physical activity 
Physical activity helps those with early breast cancer manage their condition by improving physical and 
psychosocial well-being [54-62]. There is also preliminary evidence that physical activity may have a role in 
supportive care for the management of metastatic cancer [79, 81, 82, 87, 93, 94]. The findings of Chapters 2 
and 3 will assist in the challenge to develop an intervention which encourages women living with metastatic 
disease to be physically active. Tools that adequately capture physical activity are important for monitoring 
and encouraging participation in the intervention.    
There is a diverse range of direct and indirect methods available for measuring physical activity. They adopt 
approaches such as behavioural observation, questionnaires, motion sensors and calorimetry [98]. All 
techniques have inherent strengths and weaknesses. The method adopted by researchers and clinicians is 
often determined by affordability, participant burden, sample size, age and the outcome of interest.   
Indirect physical activity measurement 
There is a large array of indirect measures available to measure physical activity, including questionnaires 
and activity logs. In surveillance, these are often preferred over direct methods as they are practical, cheap, 
of low burden and easy to administer to large cohorts. There are many questionnaires available for capturing 
physical activity in healthy adults, including the Recent Physical Activity Questionnaire (RPAQ) [99], PA 
Assessment Tool (PAAT) [100] and Human Activity Profile (HAP) [101]. Questionnaires have also been 
developed for more defined populations, such as the Community Health Activities Model Program for 
Seniors (CHAMPS) [102] and the Physical Activity Scale for the Elderly (PASE) [103], designed for older adults. 
Two questionnaires commonly used to assess physical activity in oncology research are the Godin Leisure 
Time Leisure-Time Exercise Questionnaire (GLTEQ) [104] and the International Physical Activity 
Questionnaire (IPAQ) 
The GLTEQ is a short four-item self-administered questionnaire. It captures the frequency of bouts of at least 
15 minutes of light-intensity, moderate-intensity and vigorous-intensity physical activity during a typical 
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week [104]. The number of bouts at each level of intensity is multiplied by the corresponding metabolic 
equivalent (MET) to give a Leisure Score Index (LSI) [104]. The LSI can be used to rank individuals or to 
classify their level of activity. Individuals with an LSI ≥ 24 are classified as active and meeting physical activity 
guidelines, whilst individuals with an LSI <24 are classified as being insufficiently active [105]. Due to the 
brevity and simple administration of the GLTEQ, it was used in Chapters 2 and 3 to establish physical activity 
levels of the cohort.  
One disadvantage of the GLTEQ is that it does not obtain information on the time spent at each level of 
intensity. Due to this weakness, the IPAQ [106] was adopted to assess behaviour change for the physical 
activity intervention described in Chapter 4. The IPAQ captures duration and frequency of physical activity of 
at least 10 minutes, across domains of leisure, work, transportation and household duties during the 
preceding week [106]. The number of minutes per week is obtained for walking, moderate-intensity and 
vigorous-intensity activity. The minutes for each category of activity are multiplied by the corresponding 
metabolic equivalent (MET) and summed to give MET-minutes per week (MET-min•wk-1). To gain substantial 
health benefits through physical activity, the American College of Sports Medicine (ACSM) recommends at 
least 500-1000 MET-min•wk-1 [107]. Whilst the GLTEQ and IPAQ are both acceptable tools for measuring 
physical activity [105, 106], there are inherent limitations with self-report questionnaires, such as recall bias 
which may lead to over or underestimating physical activity [108]. The GLTEQ and IPAQ have been adopted 
throughout this thesis to supplement quantification by physical activity monitors.  
Direct physical activity measurement 
Direct measurements assess energy expenditure or movement and generally provide a more detailed and 
accurate measure of physical activity compared to indirect measures. The current reference method for the 
validation of physical activity in the field is doubly labelled water (DLW) [98]. It is used to measure total 
energy expenditure (TEE) in free-living, usually over a period of at least one week. Physical activity energy 
expenditure (PAEE) can also be calculated from DLW TEE by removing the resting metabolic rate (RMR) and 
the thermic effect of food [109].However, the use of DLW is limited by its high cost and complex 
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methodology.  As a consequence, more practical and affordable approaches to measuring physical activity 
are necessary.  
One of the earliest and most direct methods of measuring physical activity is through time-and-motion 
observation. A trained individual observes physical activity behaviours either live or on a video, and codes 
behaviours into categories whilst obtaining contextual information [110]. This provides qualitative and 
quantitative information and the ability to target specific physical activity behaviours. Direct observation is 
labour intensive and time-consuming, making it impractical over long periods.  
Another of the early adopted methods for measuring physical activity is heart rate monitoring. Reviews have 
found that whilst energy expenditure at a group level is reasonably well predicted using heart rate, there are 
significant differences at an individual level [111]. The inaccuracy stems from factors such as caffeine, stress 
and body position, which disrupt the otherwise linear relationship between heart rate and energy 
expenditure [112].  
Over the past decade, wearable physical activity monitors have evolved as a promising tool for measuring 
physical activity. These monitors can be worn for extended periods of time, allowing free-living physical 
activity to be captured. Monitors may be simple such as a pedometer to measure steps or include an 
accelerometer that quantifies the frequency, intensity and duration of physical activity. In addition to an 
accelerometer, more advanced monitors may also capture information such as heart rate, location and body 
position.     
Two popular physical activity monitors amongst researchers are the SenseWear® and the Actigraph™. The 
SenseWear® integrates an accelerometer and multiple sensors that capture skin temperature, heat flux and 
galvanic skin response [113]. The data captured by the SenseWear® is processed by proprietary software to 
estimate energy expenditure. The Actigraph™ is a small tri-axial accelerometer worn at the waist, which 
records body movements as activity “counts” and uses these to predict energy expenditure. The validation 
of these two devices to measure energy expenditure has been primarily limited to healthy young adults and 
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confined to controlled laboratory environments [113, 114]. Few investigations have examined their validity 
under free-living conditions and their accuracy in similarly-aged women to those with metastatic breast 
cancer is unknown. To address this gap, both of these devices were compared to the reference method of 
DLW in older women during free-living in Chapter 5. Based on accuracy and reliability in the laboratory [115], 
the SenseWear® was also adopted to measure energy expenditure in the cross-sectional study of physical 
fitness in women living with metastatic disease (Chapter 2).  
Consumer- and research-based wearable physical activity monitors are constantly appearing in the 
marketplace. In recent years, the ActiHeart® has emerged as a promising tool for predicting physical activity 
in research settings. It attaches to two chest electrodes, introducing a unique opportunity for researchers to 
present the device to participants as a heart monitor for determining safety without revealing its primary 
purpose. This allows for true habitual physical activity behaviour to be captured without providing 
motivation for increased activity as is often seen with monitoring [116]. The ActiHeart® combines heart rate 
with an accelerometer, allowing it to capture activities of the lower limb, such as cycling, that other physical 
activity monitors are unable to detect.  As the ActiHeart® is waterproof, it can be worn at all times 
throughout the monitoring period, including during water activities. Validation studies of the ActiHeart® 
have produced conflicting results [117, 118], and its ability to accurately measure physical activity in older 
women is unknown. It was therefore included alongside the Actigraph™ and SenseWear® in the physical 
activity monitor validation study (Chapter 5). Due to the favourable features of the ActiHeart® that are not 
present in other monitors, it was also adopted to measure physical activity levels throughout the physical 
activity intervention in Chapter 4. 
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Assessment of physical fitness 
In addition to physical activity, physical fitness is considered a significant indicator of mortality and morbidity 
[119]. Physical fitness also impacts on independence and quality of life, as a reasonable level of fitness is 
required to carry out activities of daily living. Measurements of fitness can be used to identify areas of 
physical function that require attention and to assess change that occurs with the implementation of a 
physical activity program.  
There are a number of measurement approaches available to quantify physical fitness. The selection is based 
on many factors including the physiological variables of interest, access to equipment, the expertise of the 
assessor and characteristics of the participant. The most accurate tests are typically laboratory or gym-
based, requiring expensive equipment, time and expertise. However, in several settings such as in the 
community, conducting such assessments is not feasible. Many field tests have therefore been designed that 
can be conducted to provide alternative measures of fitness using minimal equipment and resources.  
As the studies in this thesis were designed to be carried out in the home, a number of field tests were 
adopted to assess aerobic fitness and muscle strength. A maximal aerobic fitness assessment, such as the 
beep test [120], can be carried out in the field and provides an accurate prediction of aerobic fitness. 
However, a maximal test was not appropriate for this metastatic population due to safety concerns and the 
inability to have medical personnel present for testing. As an alternative, sub-maximal tests such as the 
YMCA Step Test [121], the Rockport Walking Test [122] and the Modified Canadian Aerobic Fitness Test 
(mCAFT) were considered [123, 124]. The mCAFT involves stepping up and down double steps to a set 
cadence and allows maximal oxygen consumption (VO2max) to be predicted from published equations [123]. 
Whilst not as accurate as a maximal test, the mCAFT was adopted as it has shown to be no different to a 
maximal treadmill test in a population similarly-aged to women living with metastatic breast cancer [125].   
Isokinetic testing devices are considered the gold standard for assessing muscle strength [126]. These 
machines are typically located in research centres or gyms and are not appropriate for field testing due to 
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their size. An inexpensive and simple alternative for assessing muscle strength in the field is dynamometry. A 
systematic review which compared dynamometry to isokinetic testing concluded that dynamometry had 
moderate-to-good validity and reliability [126]. Given dynamometry’s portability, cost and ease of use, it is 
considered an adequate tool for muscle strength assessment. Dynamometry was used to measure grip 
strength and lower limb strength throughout this thesis.      
Patient reported outcomes  
Many tools have been developed to assess patient-reported outcomes in breast cancer patients. Some, such 
as the Medical Outcomes Study 36-Item Health Survey (SF-36) and Medical Outcomes Study 8-Item Health 
Survey (SF-8), are generic measures designed to capture quality of life in a wide range of conditions and with 
a general population [127, 128]. Other generic surveys, including the European Quality of Life Questionnaire 
(EuroQol; EQ-5D) [129], are widely used for determining quality-adjusted life years associated with a health 
state. The EQ-5D is recommended for use in evaluative studies and policy research and can also be used for 
economic evaluation. Whilst generic measures allow comparison of quality of life across different conditions, 
disease-specific instruments may capture symptoms and distress that are of more relevance to women living 
with breast cancer [130].  
The disease-specific European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire (EORTC QLQ-C30) was designed for use in cancer patients [131]. The EORTC QLQ-C30 is a 
reliable and valid measure that captures global quality of life and five domains of function; role, social, 
emotional, cognitive and physical. A high score on a functional scale represents a high level of functioning 
[132]. Symptoms including fatigue, nausea/vomiting, pain, dyspnoea, insomnia, appetite, diarrhoea and 
constipation are also evaluated [132]. A high symptom score represents high symptom burden. EORTC QLQ-
C30 normative values for women living with metastatic breast cancer are presented in Table 6 [132]. The 
EORTC QLQ-C30 was used to assess health-related quality of life and symptom burden in Chapters 2-4.    
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Table 6. EORTC QLQ-30 normative values for women living with metastatic breast cancer  
 
Given the prevalence and debilitating nature of cancer-related fatigue [43], it was important to ensure 
fatigue was captured reliably. Whilst the EORTC QLQ-C30 contains a single fatigue item, more extensive 
fatigue-specific scales possess stronger psychometric properties [133]. There are a number of scales 
designed to measure fatigue specifically in cancer patients, including the Brief Fatigue Inventory (BFI) [134] 
and the Fatigue Severity Scale (FSS) [135]. Of the available fatigue scales, a systematic review of instruments 
recommends the Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F) due to its robust 
psychometric properties [133]. The FACIT-F consists of 13 items assessing tiredness, weakness and trouble 
with usual activities. A higher score indicates less fatigue, scored out of a maximum of 52 [136]. Reference 
values for women living with metastatic breast cancer have not been established. One examination in this 
population reported the mean FACIT-F score of 90 women was 32 [137]. Although the FACIT-Fatigue was 
initially developed to evaluate fatigue in cancer patients, it has also been validated in a general population 
[136]. Not surprisingly, a general population reported lower levels of fatigue with an average score of 44 
[136]. The FACIT-Fatigue was adopted throughout this thesis to examine the intensity of fatigue and its 
impact on daily life.  
With the potential for the physical and psychosocial sequelae of metastatic breast cancer to impact on 
independence, it may also impinge on an individual’s ability to continue daily life in their environment of 
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choice. The Life-Space Assessment (LSA) is a relatively new tool that captures the spatial environment one 
occupies in daily living by determining how frequently they travel to various locations within and outside of 
the home, and the need for assistance when moving around [138]. The questionnaire is scored out of 120, 
with a higher score indicative of a higher pattern of mobility. The LSA was utilised to determine how mobile 
woman are within their home and community.   
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Aims of the thesis 
Despite the benefits of exercise and physical activity in early stage breast cancer being extensively 
investigated, there are significant gaps in the knowledge around exercise and metastatic breast cancer. The 
lack of understanding of the physical capabilities of the population and the preliminary nature of exercise 
interventions in metastatic disease raised many uncertainties. In addition, the accuracy of devices used to 
measure physical activity in free-living is relatively unknown. 
The aims of this thesis were therefore to: 
1. Compare physical activity levels and physical capabilities of women with metastatic breast cancer to 
healthy counterparts to describe the impact of metastatic breast disease on physical activity level 
and physical function; 
2. Identify physical activity preferences, barriers and benefits of women with metastatic breast cancer; 
3. Based on preferences, develop and pilot a physical activity intervention for women with metastatic 
breast cancer and determine its safety and feasibility; and  
4. Evaluate the accuracy of three physical activity monitors in free-living older women in order to 
inform future studies of women living with metastatic breast cancer. 
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Abstract  
Physical activity may help community-dwelling women with metastatic breast cancer to live well and to manage their disease. 
Understanding their specific physical activity interests may be beneficial in the development of interventions to enhance adherence 
and efficacy. The aims of this project were to determine physical activity preferences and to identify perceived barriers and benefits 
of activity, in women with metastatic breast cancer. Characteristics associated with interest in physical activity were also explored. 
Participants (n=62) comprised community-dwelling and ambulatory women diagnosed with metastatic breast cancer, with a mean 
age of 58.2 (9.5) y. Following the physical and patient-reported outcome assessment described in Chapter 2, women completed a 
structured interview to determine physical activity preferences, barriers and benefits. Seventy-four percent were interested in a 
physical activity program. There was a strong preference for home-based activity (72%), with the majority preferring to walk (89%). 
The most common barrier to participation was other commitments (20%). Perceived benefits of physical activity included increased 
energy (33%). In conclusion, the majority of women expressed interest in a physical activity program and identified strong 
preferences regarding mode and environment of activity. Understanding physical activity preferences, perceived benefits and barriers 
facilitates the design of an intervention that enhances the likelihood of being effective and acceptable in this unique population. 
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Introduction 
Breast cancer is the most common cancer among women in Australia [1]. The risk of being diagnosed with breast cancer before the 
age of 85 is one in eight [1]. For those who present with metastatic disease, the five-year relative survival is 41% [1]. As survival rates 
improve with advancements in the detection and treatment of metastatic breast cancer, promoting a healthy lifestyle to optimise 
well-being in women living with this condition becomes increasingly important.  
Despite the importance, research overall has predominantly focused on the adverse health outcomes and negative experiences of 
women living with metastatic breast cancer [2]. This lack of focus on living well is reflected in a recent study that reported whilst 
women were positive about the medical management of their disease, many were dissatisfied with the support given to manage their 
side-effects to ensure good overall quality of life [3]. As women with metastatic breast cancer focus on living well with their disease, 
one coping strategy that has been identified is increasing physical activity [4].    
In women with early breast cancer, physical activity has been widely examined and proven to alleviate side effects and improve 
quality of life [5, 6]. The same focus has not been directed to women living with metastatic breast cancer. Only a few trials have been 
conducted in this population [7-9], of which the most recent investigated the efficacy of an aerobic exercise intervention with 
equivocal outcomes [10]. There are also a small number of studies in individuals with metastatic disease originating from a range of 
other tumours [11-14]. A systematic review suggests that increased levels of physical activity may have physical and psychosocial 
benefits, including assisting women with metastatic disease to live well [15]. 
Commencement and adherence to a physical activity program are difficult for the general population, and even more challenging for 
those living with cancer [16]. As described in Chapter 2, women with metastatic breast disease are approximately 50% less active than 
a healthy cohort. Given their decreased activity and the potential role of physical activity, the design of interventions based on 
physical activity preferences may be beneficial for ensuring engagement in this unique population.  
One cross-sectional study surveyed activity preferences amongst community-dwelling palliative care patients and observed that more 
than 75% were interested in participating in a physical activity program [17]. These findings suggest that women living with metastatic 
breast cancer may also be interested in increasing physical activity or commencing structured exercise in their daily lives. 
62 
 
Physical activity may help community-dwelling women with metastatic breast cancer to live well and to manage their disease. 
However, little is known about their specific physical activity interests. Such knowledge may assist in the design of interventions to 
enhance adherence and maximise efficacy. The purpose of this study was to i) determine physical activity preferences, and to identify 
perceived barriers and benefits to activity in women with metastatic breast cancer and ii) explore characteristics associated with 
interest in commencing a physical activity program.      
Methods 
Design 
Structured interviews were completed with women with metastatic breast cancer following participation in the cross-sectional study 
described in Chapter 2. This study explored the differences in physical activity level and fitness between this metastatic population 
and healthy controls.   
Participants 
Sixty-two women with metastatic breast cancer were recruited from outpatient clinics of six Sydney cancer centres between May 
2011 and January 2013. During a routine clinic visit, women were invited to participate in the study by their oncologist or breast 
nurse. Women were eligible if they had a confirmed metastatic breast cancer (Stage IV) diagnosis, were living in the community and 
ambulatory (Eastern Cooperative Oncology Group Performance Status (ECOG) ≤3 [18]), able to communicate in English and had a 
clinician-estimated life expectancy greater than 6 months. 
The study was approved by the Human Research Ethics Committee of the Sydney South West Area Health Service (X10-0308) and all 
women provided written informed consent.  
Protocol 
An interview was conducted one week following the assessment of physical fitness, physical activity level and patient-reported 
outcomes reported in Chapter 2.  
Identification of physical activity preferences, barriers and benefits 
Perceptions of physical activity were obtained from a structured interview completed face-to-face or via telephone. The first question 
addressed interest in participating in a program designed to increase physical activity. For women who answered “no” to this 
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question, the interview was discontinued. For women who expressed interest in a program, the interview continued and women 
were asked to rate confidence in their ability to increase physical activity on a 10-point Likert scale. Women were then asked to 
indicate their interest in receiving professional support for physical activity as either ‘definitely,’ ‘probably,’ ‘unsure’, ‘probably not’ 
and ‘definitely not’. With open-ended questions, women were asked to indicate the following: favoured environment for exercise, 
preferred mode of exercise, greatest perceived barriers to increasing or maintaining physical activity levels, and largest perceived 
benefits of increasing their physical activity.  
Factors associated with interest in physical activity 
Factors were drawn from measures related to physical function and patient-reported outcomes, further described in Chapter 2.    
Demographic and clinical information. Demographic information was collected. Medical history included medications, location of 
metastases and year of primary and metastatic cancer diagnoses. 
Physical Measures. Anthropometric information including height and weight was collected. Physical activity was assessed using the 
Godin-Shephard Leisure-Time Physical Activity Questionnaire (GLTPAQ) [19]. Women who scored ≥24 on the moderate-to-strenuous 
leisure score index (LSI) were classified as active, and women who scored <24 were classified as inactive [20]. Women categorised as 
active according to the GLTPAQ were also classified as achieving the current American College of Sports Medicine (ACSM) physical 
activity guidelines for cardiorespiratory exercise [20, 21]. The Modified Canadian Aerobic Fitness Test (mCAFT) was used to estimate 
aerobic fitness [22]. This fitness estimate was then compared to population normative values [23] and women were classified as being 
above or below average based on age. Dynamometry was used to measure handgrip (Jamar Plus+; Sammons Preston Rolyon, 
Bolingbrook, USA) [24] and lower limb strength (Back-D; Takei Kiki Kogyo, Tokyo, Japan) [25]. 
Patient-Reported Outcomes. The 30-item European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 
(EORTC QLQ-30) was used to assess physical, social, role, cognitive and emotional functioning, and a range of symptoms including 
fatigue, nausea and vomiting, diarrhoea, dyspnoea, pain, appetite loss, insomnia and constipation [26]. For each functional scale, a 
higher score represented better well-being. Women with a symptom score above 50 indicated a moderate to high level of need [27], 
and these women were classified as being symptomatic.  
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Statistical analyses 
Descriptive statistics were used to describe participant characteristics and physical activity preferences, barriers and benefits. Women 
were dichotomised as to whether or not they expressed interest in a physical activity program. The association between interest and 
each potential predictor was explored using Chi Square analysis.  To prepare continuous data for Chi Square analysis, a receiver 
operating curve (ROC) was used to identify the optimal predictor cut-off point. Associations with cell frequencies less than five were 
not considered further. Means and standard deviations are presented unless otherwise stated.  Statistical analyses were performed 
using IBM SPSS Version 20 for Windows (IBM Corp. Somers, NY). 
Results 
Demographic and clinical characteristics are reported in Table 1. The mean age of participants was 58.2 (9.5) y and their mean body 
mass index (BMI) was 27.0 (5.7) kg•m-2. The median and interquartile range of duration since metastatic disease onset was 2.0 y (1.0 
to 4.0 y). Twenty-four percent of women (n=15) met current physical activity recommendations.  
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Table 1. Demographic and clinical characteristics of participants 
Characteristics All  
(n=62) 
Interest in PA  
(n=46) 
No Interest in PA  
(n=16) 
Demographic     
Age (y; mean (SD)) 58.2 (9.5) 57.1 (9.2) 61.3 (9.9) 
Living with others (n (%)) 49 (79) 35 (76) 14 (88) 
Not working (n (%)) 46 (74) 33 (72) 13 (81) 
Clinical    
Time since primary BC diagnosis  
(y; median (IQR)) 
6.5 (3.0 to 11.0) 7.0 (3.9 to 10.0) 5.0 (2.3 to 11.8) 
Time since MET diagnosis  
(y; median (IQR)) 
2.0 (1.0 to 4.0) 2.0 (1.0 to 4.0) 1.0 (1.0 to 3.0) 
ECOG (n (%))    
0 33 (56) 25 (54) 8 (50) 
1 17 (29) 12 (26) 5 (31) 
2 7 (12) 5 (11) 2 (13) 
3 2 (3) 1 (2) 1 (6) 
Location of Metastasis (n (%))    
Bone Only 17 (27) 12 (26) 5 (31) 
Visceral Only 23 (37) 18 (39) 5 (31) 
Bone and Visceral 22 (36) 16 (35) 6 (38) 
Current Treatment (n (%))    
Hormone Therapy 24 (39) 19 (41) 5 (31) 
Chemotherapy: Oral 18 (29) 15 (33) 3 (19) 
Chemotherapy: IV 13 (21)  9 (20) 4 (25) 
Trastuzumab 4 (6) 0 (0) 4 (25) 
No current treatment 3 (5) 3 (7) 0 (0) 
Lymphoedema present (n (%)) 13 (21) 10 (22) 3 (19) 
Number of comorbidities (n (%)) 2.6 (1.8) 2.7 (1.7) 2.4 (2.2) 
Physical    
BMI (kg•m
-2
; mean (SD)) 27.0 (5.7) 27.1 (5.9) 26.4 (5.0) 
Active (n (%)) 15 (24) 10 (22) 5 (32) 
Fitness above average* (n (%)) 18 (38) 14 (38) 4 (40) 
Handgrip strength (kg; mean (SD)) 26.7 (6.1) 26.7 (5.1) 26.9 (8.7) 
Lower limb strength (kg; mean (SD)) 54.1 (22.3) 55.9 (21.3) 48.2 (25.4) 
Patient-Reported Outcomes    
Function (mean (SD))    
Physical 78.6 (16.5) 78.1 (15.9) 80.0 (18.5) 
Role 78.2 (22.9) 77.2 (23.7) 81.3 (21.0) 
Emotional 77.7 (19.7) 74.8 (20.1)  85.9 (16.3) 
Cognitive  83.6 (14.9) 83.0 (14.7) 85.4 (16.0) 
Social 74.7 (24.7) 74.6 (24.0) 75.0 (27.2) 
Symptomatic (n (%))    
Fatigue 14 (23) 11 (24) 3 (19) 
Nausea/Vomiting 3 (5) 2 (4) 1 (6) 
Pain 11 (18) 9 (20) 2 (13) 
Dyspnoea 10 (16) 9 (20) 1 (6) 
*ACSM age-based population norms [23], BC=breast cancer; MET=metastatic breast cancer; PA= physical activity 
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Seventy-four percent of participants (n=46) reported that they would be interested in participating in a program aimed at increasing 
their level of physical activity. The majority of participants preferred a program that could be carried out in or near their own home 
(72%), with walking (89%) and swimming (28%) being the most popular modalities of activity (Table 2). Forty percent of women were 
extremely confident in increasing their level of physical activity, with an average of 7.9 on a Likert scale of 1-10. 
 
Table 2. Physical activity preferences of participants who were interested in participating in a physical activity program  
 
  n=46 % 
How would you rate your confidence in your ability to increase your physical activity 
level if you decided that you really wanted to? 
  
1-2 (Not at all confident) 0 0 
3-5 6 14 
6-8 20 46 
9-10 (Extremely confident)  17 40 
How interested would you be in receiving professional support and encouragement 
as you try to increase your physical activity? 
  
Definitely not/Probably not 1 2 
Unsure 2 5 
Definitely/Probably 41 93 
If you were to participate in a physical activity program, in what environment/s 
would you prefer to perform exercise?* 
  
At home 33 72 
Group environment (e.g. community group) 13 28 
In a gym 18 39 
If you were to participate in a physical activity program, what type of exercise would 
you like to perform?* 
  
Walking 41 89 
Swimming 13 28 
Cycling 2 4 
Aerobics 3 7 
Resistance training 9 20 
Aquaerobics 5 11 
Wii/Xbox 1 2 
Tai Chi 3 7 
Yoga 3 7 
Dragonboating 2 4 
Dancing 1 2 
*Participants may have selected multiple responses 
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Sixteen women (26%) were not interested in commencing a physical activity program. Reasons for not wanting to participate included 
being too ill (n=5), already doing enough exercise (n=4), too old (n=3), not enough time (n=3) and musculoskeletal concerns (n=1). Chi 
square analysis revealed there was no pattern with respect to age, time since diagnosis, location of metastasis or any other physical 
function or patient-reported outcome between those who did and did not express interest in a physical activity program.  
Eighty-nine percent of those participants interested in physical activity identified barriers to commencing a program (Figure 1). More 
than half of the identified barriers may be related to their disease or treatment (63%), with the most common being pain (17%). The 
proportion of inactive women who reported a disease or treatment-related barrier (67%) was higher than in those who were already 
active (40%). Barriers which did not appear to be related to disease course were also identified, including other commitments (20%), 
motivation (13%) and access to facilities (7%).  
Of those interested in physical activity, perceived benefits of commencing a program included increased energy (33%), feeling better 
(28%), improved psychological well-being (26%) and improved fitness (24%) (Figure 1). Increased energy was identified as a potential 
benefit in 60% of women who were already active compared to 25% in women who were inactive.   
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Figure 1. Barriers and benefits to increasing physical activity identified by participants interested in a physical activity program (n=46).  
The individual barriers and benefits are solid grey bars.  Hatched bars represent the percentage of participants who identified any 
barrier related or unrelated to treatment. Women could identify multiple barriers and benefits. 
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Discussion 
Side effects of treatment for metastatic breast cancer can have a significant impact on health and quality of life. Despite this, women 
perceive that their healthcare providers often overlook the management of side effects, and want greater focus placed on living well 
with their disease [3]. Preliminary research has shown that for some women with metastatic breast cancer, increased physical activity 
may be beneficial for improving physical and psychosocial well-being [15]. Determination of preferences for physical activity and an 
understanding of current exercise behaviours may assist in the development of interventions designed to enhance adherence and 
effectiveness. 
Similar to findings from participants living in community-dwelling palliative care [17], the majority of women in this cohort reported 
interest in commencing a program to increase their physical activity, with a preference for a home-based intervention. Whilst the 
palliative care cohort had an expected survival of less than one year, the participants in the current study had a life expectancy of at 
least six months, with some likely to survive for several years. Despite metastatic patients expressing a preference for home-based 
activity, preliminary exercise intervention trials have typically been conducted in a gymnasium, hospital or community centre [9, 13, 
28]. In recently reported physical activity research of women living with metastatic breast cancer, despite all participants being 
provided with a gym membership and exercise coaching, the majority opted for a home-based program [10].  Although home-based 
activity present challenges such as maintaining adherence and compliance by the participant to a program, the integration of an 
intervention into the home has advantages over these resource-intensive interventions and has the ability to be delivered to the 
community on a large scale.  
Women identified walking as the most favoured activity, similar to trends observed in both palliative care patients [17] and cancer 
survivors [29, 30], as well as in a general older population [31]. Walking programs are advantageous as they require minimal 
supervision, cost and equipment, and can be undertaken at a time suitable to the individual.  Advances in the development of e-
technology for health means that there is now a range of devices on offer to support exercise prescription with minimal supervision, 
including smartphone applications which can be used to monitor physical activity. A slightly more sophisticated approach that has 
recently attracted consumer interest is fitness trackers. Wearable devices like the FitBit (Fitbit Inc., San Francisco, CA) and Shine 
(Misfit Wearables, San Francisco, CA) use accelerometer-based technology to capture data, including information such as the number 
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of steps walked, quality of sleep and estimated energy expenditure. Many of these devices provide engaging visual feedback on 
progress towards individualised goals. Incorporating the use of this technology into a physical activity program may be beneficial for 
increasing motivation and improving adherence [32].  
The most commonly reported perceived benefits of increasing physical activity identified by women living with metastatic cancer 
were increased energy, feeling better and improved psychological well-being. A higher proportion of women who were already active 
reported benefits relating to energy and psychological well-being compared to inactive women. Previous research has suggested that 
cancer survivors may only engage in regular physical activity if they perceive that participation will decrease treatment-related side 
effects [33]. In addition, participation in physical activity may strengthen perceptions that physical activity may attenuate treatment-
related side effects such as fatigue [33]. Many women in this cohort appear unaware of the benefits of physical activity for symptom 
management [15], highlighting a potential role for patient education. Further research is warranted to explore the impact of physical 
activity participation and education on the perception of barriers and benefits in those with metastatic disease.    
Perceived barriers play a major role in physical activity participation. Categorisation of barriers as being either health-related or 
unrelated to disease course resulted in an almost equal number of participants reporting barriers under each category. The 
identification of time constraints, lack of motivation and apathy as barriers to physical activity is not a novel finding, with similar 
barriers reported by cancer survivors [34, 35]. Although not explored, some health-related barriers such as pain may also be due to 
other comorbidities or age-related ailments.  While some barriers may not require oversight by a skilled fitness professional, women 
who experience barriers such as dyspnoea and pain may benefit from starting a program under the guidance of an exercise specialist.  
Despite identifying barriers, most women were confident in their ability to increase physical activity. Comparison with prior studies is 
limited due to the paucity of studies on physical activity self-efficacy in individuals with metastatic disease. One study evaluating self-
efficacy found a mean value of 41% among 86 women receiving adjuvant breast cancer treatment [38], lower than in the present 
study (7.9 on a 10-point Likert scale). This variance may be explained by the  cohort of women in the present study having been 
previously exposed to an acute bout of physical testing (see Chapter 2), which has been shown to increase physical activity self-
efficacy through successful past performance accomplishments [39]. Whilst self-efficacy is considered the primary determinant of 
behaviour change [40], it should be noted that outcome expectations also have an influential role [41]. To ensure compliance with a 
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physical activity program, women with metastatic breast cancer would likely require clinician support to establish informed 
expectations and overcome barriers to participation.    
The absence of an association between physical function and patient-reported outcomes between those who did and did not express 
interest in a physical activity program is of importance. In contrast to previous research in cancer survivors [29, 30], the current study 
did not find age to be a significant contributor to interest in physical activity. This may be the result of medical management and 
secondary deconditioning significantly decreasing physical capacity in this metastatic population, irrespective of age. Notably, there 
was no difference in interest in physical activity based on quality of life, symptom severity or clinical characteristics, including the 
location of the metastases. This indicates that women who are unwell are not necessarily less likely to be interested in physical 
activity than women who are well.   
There may be an expectation that women living with metastatic breast cancer are deconditioned and sedentary. However, 24% of our 
cohort met current recommended physical activity guidelines for cardiorespiratory exercise [20], demonstrating that at least a small 
group within this population were capable of being physically active. Findings from Chapter 2 demonstrated that over 30% of the 
cohort possessed above average aerobic fitness for their age. Nevertheless, there was also a substantial proportion of the cohort who 
were inactive. Similar to the therapeutic role of physical activity in many chronic conditions such as heart disease, hypertension, type 
2 diabetes and osteoporosis [21], physical activity also has a potential role in the management of metastatic disease [15].  
There were some limitations inherent in this study. There was a possibility of clinician bias in referring patients to the study, and a 
response-bias whereby participants with a particular interest in fitness or with higher physical capacity volunteered. Conversations 
between the research team and the participants while completing the assessments in Chapter 2 may have influenced attitudes 
towards physical activity. We did not collect information about pre-cancer diagnosis activity levels, which may have impacted on 
preferences and attitudes towards a physical activity program. To participate in this study, participants had to be community-dwelling 
and ambulatory, limiting the generalisability of these findings to people with more debilitating disease.   
In conclusion, the high level of interest in a physical activity program, coupled with a portion of women already meeting physical 
activity guidelines, suggests feasibility for a program in those living with metastatic breast cancer. There was a strong preference for a 
home-based program, with walking the favoured type of activity. Insight into physical activity preferences, perceived benefits and 
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barriers facilitates the design of an intervention that enhances the likelihood of being both effective and acceptable in this unique 
population. 
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Chapter 4:  
Safety and efficacy of a physical activity program for 
women with metastatic breast cancer 
  
76 
 
Abstract 
Background: Physical activity for women with early breast cancer is well recognised for improving quality of life.  Whilst typically 
excluded from interventions, women with metastatic breast cancer may also benefit from physical activity.  
Objective: To i) investigate the safety and feasibility of a partially supervised physical activity program for women with metastatic 
breast cancer and ii) explore the efficacy of the program. 
Methods: Fourteen women with metastatic breast cancer were randomised to either a control group or an 8-week home-based 
physical activity intervention comprising of supervised resistance training and an unsupervised walking program.  
Results: The recruitment rate was 93%. Adherence to the resistance and walking components of the program was 100% and 25%, 
respectively. No adverse events were reported. When the mean change scores from baseline to post-intervention were compared, 
trends in favour of the exercise group over the control group were observed for 6MWT distance (+40 ± 23m vs. -46m ± 56m, 
respectively) and FACIT-Fatigue score (+5.6 ± 3.2 vs. -1.8 ± 3.9, respectively).   
Limitations: The recruitment strategy used targeted women who were high functioning and excluded those confined to a chair or 
bed. The sample size was small, limiting the power of between-group comparisons. 
Conclusions: A partially supervised home-based physical activity program for women with metastatic breast cancer is feasible and 
safe. The dose of the resistance training component was well tolerated and achievable in this population. In contrast, adherence and 
compliance to the walking program were poor. Preliminary data suggest a physical activity program may lead to improvements in 
physical capacity and may help women to live well with their disease. There is a need for future research to identify safe and optimal 
exercise parameters.    
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Introduction 
Advances in the management of metastatic breast cancer mean that for many women their disease can be viewed as chronic, albeit 
incurable [1]. With survival increasing, these women may live for several years with a high level of symptom burden, commonly 
experiencing fatigue, depression, insomnia and pain [2-4]. However, as seen in Chapter 2, some women living with metastatic disease 
are not significantly debilitated and are able to continue the roles and activities similar to pre-diagnosis [5]. Whilst healthcare 
providers often focus on survival, women living with metastatic breast cancer want more emphasis placed on alleviating symptoms 
and living well with their disease [6]. One of many strategies identified by women for living well is increasing daily physical activity [7].    
For women with early breast cancer, the physical and psychosocial benefits of physical activity and exercise have been well 
documented [8, 9]. These programs generally focus on improving quality of life, with prescription similar to that for a cancer-free 
population. Women with metastatic disease have traditionally been excluded from physical activity or exercise interventions, with 
conventional advice to avoid exercise due to fear of pathological fracture and a conservative view that fatigue is best treated with rest 
[10, 11]. However, in a systematic review of metastatic cancer, evaluation of eight studies suggested that exercise interventions had 
the potential to improve physical performance outcomes [12].  
Preliminary research of exercise programs for individuals with metastatic cancer has been typically conducted in a gymnasium, 
hospital or community centre [10, 11, 13]. Programs in these environments are generally resource intensive, requiring specialised 
equipment and supervision by exercise professionals, creating potential barriers to their translation into clinical practice. A program 
that can be delivered in the participant’s home may not only increase the potential for implementation but was also identified as a 
preference for women living with metastatic breast cancer in Chapter 3. Incorporating patient preferences in the design of a physical 
activity intervention may enhance adherence and retention to the program.  
This study evaluated a home-based physical activity intervention in community-dwelling women living with metastatic breast cancer. 
The primary purpose of this phase I/II study was to evaluate the feasibility and safety of delivering a partially supervised program for 
this population. In addition, the efficacy of the physical activity program was explored with respect to physical performance, physical 
activity level and patient-reported outcomes.  
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Methods 
Trial Design  
This study was a pilot randomised controlled trial, adhering to the CONSORT Statement for non-pharmacological treatments [14]. 
Permuted block randomization was performed using a computer-generated random numbers list by an individual external to the 
study. Participants were stratified according to whether they presented with bone-only or visceral ± bone metastases. Randomization 
was performed in blocks of 4, 6 and 8 with an allocation ratio of 1:1 to either exercise or a control group. Sequentially numbered 
opaque envelopes containing group allocation were opened by the researcher in the presence of participants following the baseline 
assessment.    
Participants 
Women with metastatic breast cancer who participated in the studies described in Chapters 2 and 3 and resided in close proximity to 
the University of Sydney were invited to participate. Fourteen women were enrolled between October 2012 and July 2013. Inclusion 
criteria included: stage IV breast cancer, living in the community, mentally competent to follow instructions, Eastern Cooperative 
Oncology Group (ECOG) performance status of 0-3 [15], over 18 years of age and an oncologist-expected survival of at least 4 months. 
Individuals participating in regular physical activity, determined as “high” activity by the International Physical Activity Questionnaire 
(IPAQ), were excluded. Other exclusion criteria included the inability to communicate in English or experiencing pain or other 
neuromuscular or musculoskeletal symptoms that limit physical activity.  
Women in both groups completed the Physical Activity Readiness Questionnaire [16] to screen for cardiovascular, neurological and 
musculoskeletal risk factors. Participants who required medical evaluation discussed the study with their oncologist or primary care 
physician to gain medical clearance prior to enrolling in the study.  
The study was conducted in accordance with the protocol, approved by the Human Research Ethics Committee of the Sydney Local 
Health District (X11-0344). All participants provided written informed consent.  
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Intervention 
Control group (n=6) 
The control group was asked to maintain their habitual level of physical activity, and no advice on exercise or physical activity was 
provided.  
Exercise group (n=8) 
The intervention comprised an 8-week program of 16 exercise sessions conducted in the participant’s home or a local park, 
supervised by an Exercise Physiologist. An unsupervised walking program was also prescribed for the duration of the 8-week 
intervention.  
Each supervised session consisted of a 10-15 minute brisk walk followed by 30-40 minutes of resistance training. The short walk at the 
beginning of each session was monitored via a pedometer and Borg’s rating of perceived exertion (RPE), with a target zone of 11-13 
to reflect a moderate intensity [17]. By accompanying the participant on this walk, the Exercise Physiologist was able to monitor and 
provide feedback on appropriate exercise intensity. The resistance exercises included chest press, horizontal row, upright row, bicep 
curl, calf raises, lunges and either sit-to-stands or squats. Each exercise was individualised based on training experience and baseline 
strength. Upper body exercises were delivered using a Smart Stick™ and Smart Toner® (Twist Sport Conditioning Inc., North 
Vancouver, Canada) and the lower body exercises used body weight resistance, with the addition of hand weights as required. Each 
resistance exercise involved 2 sets of 10-12 repetitions, with one-minute recovery between each set. Resistance training was 
performed at a moderate intensity, targeting 6-7 out of 10 on the Adult OMNI Perceived Exertion Scale (OMNI-RES) [18]. Resistance 
training was progressive for each exercise, with resistance increased when the participant’s perceived exertion fell below the target 
range. Exercise diaries were maintained by the Exercise Physiologist at each session. 
The unsupervised walking program was conducted in the same manner as the supervised walk, with steps counted using a pedometer 
and a target RPE of 11-13 [17]. Women were asked to walk on days they were not seeing their trainer and encouraged to increase the 
number of steps taken each week by 10%.  
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Women in both groups were contacted weekly to document their physical activity outside of the study, appointments with medical or 
allied health professionals and changes to medication.  
Primary Outcomes: Feasibility and Safety  
Feasibility of the physical activity program was determined through recruitment and retention rates, adherence and compliance to 
the intervention, and safety. Recruitment rate was determined by the percentage of eligible patients who enrolled, with retention 
calculated as the percentage of participants who completed the study. Adherence and compliance rates were retrieved from exercise 
diaries and determined as outlined in Table 1. Adherence was defined as attendance at sessions, with compliance examined in terms 
of average exercise intensity and volume. Participants were considered to be adherent or compliant if they achieved at least 90% of 
the respective prescribed component. Safety was measured by the number of adverse events related to the intervention.  
Table 1.Measures of adherence and compliance to the supervised and unsupervised training components of the program.  
 
 
Supervised  
Resistance training 
Unsupervised 
 Walking program 
Adherence 
Attended sessions 
Prescribed sessions
 x  100% 
Compliance    
Exercise intensity  
Reported OMNI − RES
Prescribed OMNI − RES
 x  100% 
Reported RPE
Prescribed RPE
 x  100% 
Exercise volume 
Performed repetitions
Prescribed repetitions
 x  100% 
Performed steps
Prescribed steps
 x  100% 
 RPE=Borg’s Rating of Perceived Exertion, OMNI-RES= Adult OMNI Perceived Exertion Scale 
Secondary Outcomes: Preliminary Efficacy 
The preliminary efficacy outcomes were physical performance, physical activity level and patient-reported outcomes, assessed using 
the standardised tests described in Chapter 2. Assessments were conducted in the participant’s home or at The University of Sydney. 
All variables were measured prior to the intervention (Baseline), following the intervention (Wk8) and 8 weeks post-intervention 
(Wk16). All outcomes measures were performed by the same assessor who was not blinded to group allocation.  
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Physical Performance 
The Modified Canadian Aerobic Fitness Test (mCAFT) was used to assess aerobic fitness [19, 20].  Aerobic fitness was reported as 
VO2max  (ml•kg-1•min-1) predicted from mCAFT equations [19]. The six-minute walk test (6MWT) was used as a measure of 
functional capacity [21]. Participants were instructed to walk between two markers 20 metres apart as many times as possible in six 
minutes. The participants were asked to walk as fast as they could at a pace they could maintain for the test duration, and given 
standardised encouragement every minute. The total distance covered in six minutes was used for analysis.  
A back-leg dynamometer (Back-D; Takei Kiki Kogyo, Tokyo, Japan) [22] was used to evaluate lower limb strength (kg). Handgrip 
strength (kg) of the dominant limb was measured using hand dynamometry (Jamar Plus+; Sammons Preston Rolyon, Bolingbrook, 
USA) [23]. Women were verbally encouraged by the assessor to produce a maximal effort. Three trials were performed with each 
dynamometer, and if the relative difference was within 10%, no additional trial was required. The highest score from three 
reproducible trials was retained for analysis.  
Physical Activity  
Physical activity was determined from the International Physical Activity Questionnaire (IPAQ) [24] and from a physical activity 
monitor. The IPAQ is a simple seven-day recall measure used to quantify physical activity and is commonly used in cancer populations 
[25-27]. The total score requires the summation of minutes and frequency of physical activity, which is used to score each type of 
activity by its energy requirements to calculate a score in MET-minutes of activity per week (MET-min•wk-1) [24].  
Participants were asked to wear an ActiHeart™ physical activity monitor [28] continuously for a period of seven days. The ActiHeart™ 
device connects to two ECG electrodes under the left breast, one placed lateral of the xiphoid process and the other on the same 
horizontal plane as lateral as possible.  The ActiHeart™ combines a uniaxial accelerometer with a heart rate monitor to calculate a 
range of physical activity variables. The variable used for analysis in this study was daily physical activity energy expenditure (PAEE) 
(ActiHeart Software, Version 4, CamNtech Ltd, Cambridge, United Kingdom).  
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Patient-Reported Outcomes 
The Functional Assessment of Chronic Illness Therapy: Fatigue (FACIT-F) is designed to measure cancer fatigue [29, 30]. It was used to 
assess the severity and impact of fatigue in this study, with a maximum score of 52.  A lower score is indicative of more significant 
fatigue. 
The 30-item European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30) was also 
used [31, 32]. Items relating to physical, role, social, emotional and cognitive functioning were rated, with a higher score 
representative of better well-being. Symptoms including fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, 
constipation and diarrhoea were also rated. In contrast to the functional scales, a higher score for a symptom scale represents a 
higher burden of symptomology.  
Statistical Analyses 
Given the exploratory nature of the study, sample size was established based on available funding and resources.  Group allocation 
was coded to enable blinded analysis. Measures of feasibility and safety were determined using descriptive statistics. The unadjusted 
mean change from baseline in physical activity, physical performance and patient-reported outcomes were compared between the 
two groups using descriptive statistics. Glass’s delta was used to calculate the effect size of the intervention. An effect size of less than 
0.2 was considered small, 0.5 considered medium and more than 0.8 considered large [33]. Probability testing was not used to 
compare groups due to the small sample size. Mean and standard deviation (SD) have been reported unless otherwise stated. IBM 
SPSS version 20 for Windows (IBM Corp. Somers, NY) was used for statistical analyses. 
Results 
Recruitment and retention 
Participant disposition through recruitment, assessment and intervention phases are shown in Figure 1. Of the 18 women approached 
to participate, all expressed interest. Three women were ineligible due to already participating in regular exercise (n=2) or moving out 
of the area (n=1). Fifteen were eligible to participate, however, one woman was not able to commit to the study at the time of initial 
contact. Fourteen women were therefore enrolled into the study, generating a recruitment rate of 93%. Eight women were allocated 
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to the exercise group and six women to the control group. Retention was good in both the exercise and control groups (100% and 
83%, respectively), with one control lost to follow-up at Week 16.  
 
Figure 1. Flow of participants through study 
 
 
Participant Characteristics 
Participant characteristics are shown in Table 2. Notably, 67% in the control group were receiving chemotherapy compared to 13% in 
the exercise group.  
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Table 2. Demographic and baseline physical characteristics of the control and exercise groups. Values are mean ± SD or n (%).  
 
 
All 
n=14 
Control group 
n=6 
Exercise group 
n=8 
Age (y) 62.2 ± 10.6 65.0 ± 6.9 60.1 ± 12.7 
Height (m)  1.63 ± 0.07 1.62 ± 0.05 1.64 ± 0.08 
Body mass (kg) 75.2 ± 16.3 74.1 ± 16.9 76.1 ± 17.0 
BMI (kg•m-2) 28.3 ± 5.7 28.1 ± 5.6 28.4 ± 6.2 
Time since primary breast cancer diagnosis (y) 9.8 ± 6.5 11.0 ± 5.5 8.9 ± 7.4 
Time since metastatic breast cancer diagnosis (y) 3.5 ± 4.2 4.8 ± 4.6 2.6 ± 3.9 
Number of co-morbid conditions 3.0 ± 2.5 3.3 ± 2.6 2.8 ± 2.6 
ECOG     
0 4 (29) 2 (33) 2 (25) 
1 8 (57) 3 (50) 5 (63) 
2 2 (14) 1 (17) 1 (13) 
Location of Metastasis     
Bone Only 4 (29) 1 (17) 3 (38) 
Visceral Involvement 10 (71) 5 (83) 5 (63) 
Current Treatment     
Hormone Therapy 7 (50) 1 (17) 6 (75) 
Chemotherapy 5 (36) 4 (67) 1 (13) 
No current treatment 2 (14) 1 (17) 1 (13) 
Education     
School certificate 5 (36) 3 (50) 2 (25) 
University degree 9 (64) 3 (50) 6 (75) 
Marital Status     
Married 6 (43) 2 (33) 4 (50) 
Other 8 (57) 4 (67) 4 (50) 
Employment     
Not working 10 (71) 3 (50) 7 (88) 
Income     
≤$52,000 8 (57) 4 (67) 4 (50) 
Menopausal status     
Peri- 2 (14) 0 (0) 2 (25) 
Post- 12 (86) 6 (100) 6 (75) 
Physical performance    
VO2max (ml•kg
-1•min-1) 23.4 ± 6.3 21.9 ± 4.6 24.3 ± 7.4 
6MWT (m) 520.6 ± 116.4 506.3 ± 93.9 531.4 ± 136.2 
Leg strength (kg) 59.6 ± 17.0 62.3 ± 15.8 56.6 ± 18.6 
Hand strength (kg) 26.7 ± 5.7 26.5 ± 2.8 26.8 ± 7.4 
Physical activity    
PAEE (kJ) 2829 ± 1887 2714 ± 814 3143 ± 2362 
IPAQ (MET-min•wk-1) 1790 ± 2018 1898 ± 2471 1709 ± 1785 
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Adherence and safety 
Adherence and compliance to the supervised resistance training component of the physical activity program were excellent (Table 3). 
All eight women attended 100% of the 16 supervised sessions with all sessions completed at the prescribed intensity and volume. In 
contrast, only 2 women adhered to the walking program. Compliance with walking intensity was found in 71% of participants, 
however, no participants achieved the desired volume of walking. No adverse events or safety concerns related to the intervention 
occurred.     
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Table 3.Rates of adherence and compliance to the supervised and unsupervised training components of the program. Values are n (%).  
 
 
Supervised  
Resistance 
training 
Unsupervised 
 Walking 
program 
Adherence to prescribed sessions   
90-100% 8 (100) 2 (25) 
75-89% 0 (0) 1 (13) 
50-74% 0 (0) 3 (38) 
25-49% 0 (0) 1 (13) 
0-24% 0 (0) 1 (13) 
Compliance with exercise intensity*   
90-100% 8 (100) 5 (71) 
75-89% 0 (0) 2 (29) 
50-74% 0 (0) 0 (0) 
25-49% 0 (0) 0 (0) 
0-24% 0 (0) 0 (0) 
Compliance with exercise volume*   
90-100% 8 (100) 0 (0) 
75-89% 0 (0) 0 (0) 
50-74% 0 (0) 2 (29) 
25-49% 0 (0) 5 (29) 
0-24% 0 (0) 0 (0) 
*data missing for unsupervised component (n=1) 
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Preliminary efficacy outcomes 
Figure 2 and Table 4 present the changes in physical measures from Baseline to Week 8 and Baseline to Week 16 in both groups. A 
large effect size was observed in the exercise group for 6MWT and leg strength at both time points. Measures of physical activity and 
strength show a consistent trend in favour of the exercise group.   
Figure 2. Results of (A) 6MWT, (B) FACIT-F, (C) leg strength and (D) IPAQ in each group at each assessment. Values are mean and 95% 
confidence interval. 
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Table 4. Change in physical and activity measures from Baseline at Week 8 and Week 16  
 Wk8 – Baseline   Wk16 - Baseline     
 
Control  
Mean (SD) 
Exercise  
Mean (SD) 
Between-group 
difference (95% CI) 
Effect Size  Control 
Mean (SD) 
Exercise  
Mean (SD) 
Between-group 
difference (95% CI) 
Effect size 
Body mass (kg) 0.9 (0.8) 2.1 (2.8) 1.1 (-1.3 to 3.5) 1.45*  -0.4 (1.7) 3.1 (2.3) 3.4 (0.8 to 6.1) 2.07* 
Physical performance          
VO2max (ml•kg
-1•min-1) -0.2 (0.1) 1.6 (1.8) 1.8 (0.3 to 3.3) 14.85*  -0.2 (0.2) 0.1 (1.0) 0.2 (-1.0 to 1.3) 0.71 
6MWT (m) -46 (56) 40 (23) 86 (38 to 134) 1.54*  -11 (26) 49 (35) 59 (15 to 104) 2.26* 
Leg strength (kg) -2.8 (5.5) 7.5 (11.3) 10.3 (-0.7 to 21.2) 1.87*  1.7 (6.1) 13.5 (15.6) 11.8 (-3.1 to 26.6) 1.92* 
Hand strength (kg) 0.1 (2.2) 1.8 (1.3) 1.7 (-0.7 to 4.1) 0.76  -0.4 (1.5) 1.6 (2.2) 2.0 (-0.5 to 4.4) 1.29* 
Physical activity          
PAEE (kJ) -746 (1177) -129 (657) 494 (-561 to 1549) 0.56  -569 (1171) 293 (700) 862 (-336 to 2060) 0.74 
IPAQ  (MET-min•wk-1) -738 (1622) 228 (915) 966 (-514 to 2447) 0.60  -611 (2046) 155 (1051) 767 (-1106 to 2638) 0.37 
*denotes large effect size based on Glass’s delta >0.8, VO2max =maximal oxygen consumption, 6WMT= six-minute walk test, PAEE=physical activity energy 
expenditure, IPAQ=International Physical Activity Questionnaire  
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Patient-reported outcome data are presented in Table 5. There was an increase in physical function and 
decrease in fatigue in the exercise group as measured by the EORTC QLQ-C30 and FACIT-fatigue. A 
consistent trend in favour of the exercise group was also observed across the physical, role, emotional and 
social function scales of the EORTC QLQ-C30.  
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Table 5. Change in patient-reported measures from Baseline at Week 8 and Week 16  
 Wk8 – Baseline   Wk16 - Baseline  
 
Control  
Mean (SD) 
Exercise  
Mean (SD) 
Between-group  
difference (95% CI) 
Effect size  Control 
Mean (SD) 
Exercise  
Mean (SD) 
Between-group  
difference (95% CI) 
Effect size 
FACIT-F -1.8 (3.9) 5.6 (3.2) 7.5 (3.3 to 11.6) 1.92*  0.8 (5.7) 6.1 (3.6) 5.3 (-0.3 to 10.9) 0.93* 
EORTC QLQ-C30         
Function Scales         
Global Health -2.8 (14.6) 5.2 (15.4) 8.0 (-9.7 to 25.7) 0.55  -6.7 (10.9) 7.3 (21.6) 14.0 (-9.1 to 37.1) 1.28* 
Physical  -6.7 (7.3) 5.8 (6.6) 12.5 (4.4 to 20.6) 1.71*  1.3 (9.9) 4.2 (8.7) 2.8 (-8.6 to 14.3) 0.29 
Role -11.1 (20.2) 8.3 (8.9) 19.4 (2.1 to 36.7) 0.96*  -16.7 (20.4) 8.3 (12.4) 25.0 (3.2 to 46.8) 1.22* 
Emotional -6.9 (9.7) 7.3 (13.7) 14.2 (-0.1 to -28.6) 1.46*  5.0 (4.6) 7.3 (10.4) 2.3 (-8.7 to 13.2) 0.50 
Cognitive 2.8 (16.4) 2.1 (5.9) -0.7 (-14.2 to 12.8) 0.04  6.7 (15.0) 0 (12.6) -6.7 (-23.6 to 10.3) 0.45 
Social -8.3 (14.0) 12.5 (17.3) 20.8 (2.1 to 39.6) 1.49*  -3.3 (7.5) 4.2 (21.4) 7.5 (-14.6 to 29.6) 1.01* 
Symptoms          
Fatigue 0.0 (7.0) -6.9 (13.2) -6.9 (-20 to 6.1) 0.99*  2.2 (9.3) -5.6 (17.8) -7.8 (-26.9 to 11.4) 0.85* 
Nausea/Vomiting 0.0 (10.5) -4.2 (11.8) -4.2 (-17.4 to 9.1) 0.40  -10.0 (14.9) 2.1 (18.8) 12.1 (-9.8 to 34.0) 0.81* 
Pain 5.6 (8.6) -8.3 (19.9) -13.9 (-31.4 to 3.6) 1.61*  -6.7 (36.5) -14.6 (13.9) -7.9 (-38.9 to 23.0) 0.22 
Dyspnoea 5.6 (13.6) 0 (17.8) -5.6 (-24.6 to 13.5) 0.41  6.7 (14.9) 0 (17.8) -6.7 (-27.8 to 14.4) 0.45 
Insomnia 5.6 (25.1) 0 (17.8) -5.6 (-30.4 to 19.3) 0.22  6.7 (14.9) -4.2 (11.8) -10.8 (-27.2 to 5.5) 0.73 
Appetite Loss 11.1 (17.2) 0 (0) -11.1 (-29.2 to 7.0) 0.65  0 (0) 0 (0) 0 (0) 0 
Constipation -5.6 (13.6) 0 (17.8) 5.6 (-13.5 to 24.6) 0.41  -13.3 (18.3) 0 (17.8) 13.3 (-9.2 to 35.9) 0.73 
Diarrhoea 11.1 (27.2) 0 (0) -11.1 (-39.7 to 17.5) 0.41  6.7 (14.9) 8.3 (23.6) 1.7 (-24.5 to 27.8) 0.11 
Financial 
Difficulties 
5.6 (25.1) 0 (17.8) -5.6 (-32.9 to 21.8) 0.22  6.7 (14.9) -4.2 (11.8) -10.8 (-27.2 to 5.5) 0.73 
*denotes large effect size based on Glass’s delta >0.8
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Discussion 
This study investigated the safety and feasibility of a partially supervised home-based physical activity program for community-
dwelling women living with metastatic breast cancer. The program was well-accepted and feasible with preliminary findings 
warranting further investigation as a potentially effective intervention for improving physical function and quality of life in this 
population. 
Feasibility 
This study demonstrated the feasibility to recruit and retain patients with metastatic breast cancer into a longitudinal exercise 
intervention. Recruitment rates for resistance exercise trials in early breast cancer are typically lower than observed in this study [34-
36]. One explanation for this finding may be that the women in the present study had previously expressed interest in increasing their 
level of physical activity, following participation in the studies of physical activity and fitness presented in Chapters 2 and 3. While 
88% of women referred to the original cross-sectional study participated (Chapter 2), there may have been clinician bias whereby 
those referred were higher functioning and more motivated to participate in regular physical activity than the average metastatic 
disease population. Excellent retention to the study may be the result of the implementation of a home-based program, identified as 
a preference for physical activity in Chapter 3. This is further supported by a recent study of an aerobic intervention in the same 
metastatic population, which found that although participants were provided with a gym membership and exercise coaching, they 
primarily completed the intervention at home [37]. 
The adherence to the supervised component of the physical activity intervention was excellent, with 100% of prescribed resistance 
training sessions attended by participants. Within these sessions, compliance with prescribed intensity and volume was also high. The 
high adherence and compliance rates of resistance training may be attributed to the supervision of these sessions by an Exercise 
Physiologist, promoting participation and motivation.  
Despite both the resistance and walking components of the program being home-based, adherence to the unsupervised walking 
program was poor. The low adherence highlights the importance of the role of the Exercise Physiologist as an external motivator and 
indicates the need for strategies to promote exercise adherence in the absence of a trainer. Given that walking does not require 
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supervision by an exercise specialist, one approach may be to facilitate social support by encouraging women to walk with family or 
friends.  Whilst none of the women successfully increased their walking volume as prescribed, it was encouraging that the majority 
were compliant with walking at a moderate intensity. This finding is important as is indicates that women were able to achieve the 
desired level of intensity without the supervision of a trainer or sophisticated equipment. These findings support the implementation 
of a home-based training program on a larger scale but highlight the need to identify and include strategies to foster adherence to 
unsupervised exercise in this environment.  
Although the physical activity program was home-based, the resistance training sessions were supervised by an Exercise Physiologist. 
This level of supervision may have contributed to the lack of any adverse events related to the intervention, a finding similar to 
previous studies of individuals with metastatic disease [11, 38, 39]. However, given the large number of resources required to run this 
component of the program, it has a number of barriers for integration into care. With the high level of adherence and compliance to 
the resistance training sessions, it appears reasonable for supervision to taper off with appropriate mechanisms in place for 
maintaining adherence. Findings from this study suggest that an appropriately designed and partially supervised moderate-intensity 
resistance and lifestyle physical activity program is well tolerated and safe for some women with metastatic breast cancer. 
Efficacy Outcomes 
The between-group differences observed in measures of physical performance, physical activity and patient-reported outcomes can 
be used to inform the design of a larger randomised controlled trial. The intervention used in the current study was not only well-
tolerated, but there was a medium to large effect for all physical performance measures in the exercise group. Physical activity 
measures also favour the exercise group. However, the magnitude and direction of change differs between the IPAQ and the 
ActiHeart™. Given the limited evidence supporting IPAQ’s ability to assess change in intervention studies [40], physical activity 
measured by the ActiHeart™ may provide a more accurate insight. In addition to the positive physical outcomes, there was a trend for 
improvement in patient-reported outcomes in favour of the exercise group. These findings align with a systematic review of exercise 
in people with metastatic disease [12], suggesting that it may help women living with metastatic breast cancer to live well and to 
manage their condition.  
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Whilst this study was not powered to detect statistical significance, the consideration of clinical relevance provides further insight into 
the findings. For the physical performance measures adopted, the magnitude of clinically meaningful change has not been established 
for individuals with metastatic disease. However, one study of the 6MWT  in older adults with mild to moderate mobility limitations, 
described a small meaningful change with an increase of 19m, and a substantial change with 47m [41]. With respect to fatigue 
measured by FACIT-F, the established minimal clinically important difference in a mixed cancer population was 3 points [42]. The 
exercise group demonstrated clinically meaningful improvements in both these measures of physical function and fatigue. The 
preliminary evidence is promising and supports the need for further research to explore the most efficacious frequency, intensity, 
duration and mode of intervention in this population.    
A recent aerobic exercise trial in women with metastatic breast cancer demonstrated equivocal effects on physical function [37]. The 
authors noted the heterogeneous nature of the population and the impact this has on variations in response to exercise, limiting the 
ability to detect changes in functional outcomes. Given this heterogeneity, traditional measures used to assess such outcomes may 
not be suitable and tools that focus on the patient’s opinion of their function may be more appropriate.  For example, the Patient-
Specific Function Scale [43] allows patients to identify activities that are impacted by their condition, capturing limitations that are 
often missed in other outcomes measures.   
Study Limitations 
As a phase I/II study examining the effects of exercise in women with metastatic breast cancer, certain limitations should be 
considered when interpreting these findings. Our recruitment strategy targeted women who were high functioning and excluded 
those with ECOG 3-4. However, some women were low functioning, with three women covering ≤400m in the 6MWT.  In addition, 
two of these women were classified as ECOG 2, i.e. ambulatory and capable of self-care but unable to carry out any work activities. 
Although the intervention in this current study was found to be feasible and safe, it may not be feasible for women who spend the 
majority of their time confined to a bed or chair (i.e. ECOG 3 and 4).  Similarly, it may not be sufficiently challenging for women who 
are high functioning and active.  As seen in Chapter 2, physical capabilities are highly variable in women living with metastatic breast 
cancer. Given the disparate physical and psychosocial function observed, future interventions could be designed to target or carefully 
stratify subgroups of the metastatic population, such as on the basis of ECOG. While the benefits of exercise are well understood for 
women with early breast cancer [44-46], there is a need to address gaps in knowledge with respect to exercise and metastatic breast 
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cancer. Appropriately powered randomised controlled trials are required to confirm the safety and efficacy of physical activity 
programs in this population.  
Conclusion 
Preliminary evidence from this randomised controlled trial suggests that a partially supervised moderate-intensity resistance and 
lifestyle physical activity program for women with metastatic breast cancer is feasible and safe. The dose of the supervised resistance 
training component was well tolerated and achievable in this population. However, issues with adherence and compliance to the 
walking program were evident. Initial efficacy data suggest that a physical activity program may lead to improvements in physical 
activity level, physical fitness and functional capacity, and may help women to live well with their disease. These preliminary findings 
justify the need for future research to identify safe and optimal exercise parameters.    
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Chapter 5:  
Validation of three activity monitors for assessment of  
energy expenditure in older women 
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Abstract 
BACKGROUND: Accurate measurement of physical activity is important in the context of managing lifestyle diseases. The reference 
method for assessing total energy expenditure (TEE) and physical activity energy expenditure (PAEE) in free-living conditions is doubly 
labelled water (DLW), but it is expensive and requires technical expertise for processing and analysis. Physical activity monitors are 
therefore an attractive alternative approach for capturing energy expenditure, but their accuracy for estimating energy expenditure 
in older women remains uncertain. 
PURPOSE: This study aimed to i) validate three physical activity monitors for TEE assessment in older women under free-living 
conditions using DLW as the reference method and ii) determine the accuracy of the PAEE estimates obtained by these monitors. 
METHODS:  Thirty-three older women aged 60.7 ± 7.1 y with a BMI of 26.9 ± 5.0 kg•m-2 participated in this study. Women wore 
Actigraph™, SenseWear® and ActiHeart® physical activity monitors for 14 consecutive days. Reference values for TEE and PAEE were 
determined using a standardised protocol for DLW.  
RESULTS: A repeated measures analysis of variance determined that mean TEE did not differ significantly amongst DLW and the 
physical activity monitors (p=0.07). Actigraph™ had the highest level of agreement for TEE with DLW (rc=0.74). All monitors 
underestimated TEE by 6% compared to DLW. A repeated measures analysis of variance determined that mean PAEE differed 
amongst monitors (p<0.01). There was a significant difference between DLW and SenseWear® (p<0.01) but not between DLW and 
Actigraph™ (p=0.07) or DLW and ActiHeart® (p=0.13). PAEE obtained from DLW was underestimated by all test methods, ranging 
from 17% in ActiHeart® and Actigraph™ to 40% in SenseWear®. 
CONCLUSION: At the group level, the Actigraph™, SenseWear® and ActiHeart® demonstrated acceptable levels of agreement with a 
reference measure of TEE in older women under free-living conditions. The agreement was greater for estimating TEE than PAEE. 
Further research is required to improve the accuracy of energy expenditure estimates in these PA monitors. 
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Introduction 
Three physical activity monitors, the Actigraph™, SenseWear® and ActiHeart®, were used to describe physical activity in women living 
with metastatic breast cancer in Chapters 2 and 4. Despite their adoption for these studies, the ability of these devices to accurately 
quantify energy expenditure in this population or a similarly-aged cohort is unknown. 
With low levels of physical activity identified as a key risk factor for mortality, individuals who participate in regular physical activity 
experience better health than those who are sedentary [1, 2]. They also possess reduced risk for common chronic conditions such as 
heart disease, hypertension, depression, diabetes and breast cancer [1, 2]. Given the relationship between physical activity and health 
outcomes, the accurate measurement of physical activity is important for surveillance and evaluation of interventions.  
The most direct measure of quantifying physical activity is through time-and-motion observation, classification and analysis. However, 
this approach does not always lead to precise quantification of energy expenditure [3]. The ‘gold standard’ technique for measuring 
energy expenditure is direct calorimetry, though this approach has limited practical application for assessment under free-living 
conditions [4]. A widely acknowledged reference method for quantifying total energy expenditure (TEE) in free-living is doubly 
labelled water (DLW) [5]. DLW can also be combined with resting metabolic rate (RMR) and the thermic effect of food to provide the 
most accurate measure of free-living physical activity energy expenditure (PAEE). However, high cost and technical complexity limit 
the use of DLW in clinical and community settings [6]. In such environments, more affordable and practical methods of measuring 
energy expenditure are required.    
Researchers have expressed considerable interest in physical activity monitors in recent years as an alternative objective approach for 
measuring energy expenditure. Two of the most frequently used monitors are the Actigraph™ and SenseWear®. The Actigraph™ GT3x 
(AG) is a small tri-axial accelerometer typically worn at the waist. The SenseWear® (SW) is worn on the upper arm and includes 
multiple sensors in addition to an accelerometer. The information captured by these physical activity monitors can be used to 
estimate energy expenditure. Most validation studies of these two devices have been carried out under controlled laboratory 
conditions, with only a few investigations examining their validity in true free-living conditions. Energy expenditure estimation by the 
Actigraph™ and SenseWear® has been investigated in many populations, including children [7], healthy adults [8] and women with 
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COPD [9], with varying degrees of accuracy. The ability of these monitors to accurately capture free-living energy expenditure in older 
women has not been adequately explored. 
The ActiHeart® is one of many new physical activity monitors that has entered the marketplace and demonstrates a potential for 
increased accuracy and usability. The ActiHeart® clips onto two standard ECG chest electrodes and estimates energy expenditure by 
combining heart rate and body movement. Theoretically, the addition of heart rate should provide a better estimate of energy 
expenditure than accelerometry alone [10]. As such, the ActiHeart® is capable of capturing activities that other physical activity 
monitors are generally unable to detect, such as cycling or resistance training. The ActiHeart® is also waterproof so can be worn 
continuously throughout monitoring, including for water activities such as bathing or swimming. A small number of studies have 
produced conflicting results between the agreement of the ActiHeart® with DLW in children, young men and adults [11, 12]. The 
ability of the ActiHeart® to validly measure energy expenditure in healthy older women under free-living conditions has not been 
evaluated.  
The aim of this study was to validate the Actigraph™, SenseWear® and ActiHeart® physical activity monitors for total energy 
expenditure (TEE) assessment in older women under free-living conditions, using doubly labelled water as the reference method. The 
accuracy of physical activity energy expenditure (PAEE) estimates obtained by these monitors was also investigated.  
Methods 
Participants 
Thirty-three women aged 50 years and over participated. Women enrolled in a breast cancer research database maintained at the 
University of Sydney, including those with and without breast cancer, were contacted and invited to participate. Additional 
recruitment occurred through advertisements placed in the University of Queensland’s staff and alumni newsletters. Women were 
eligible if they were able to communicate in English and agreed to comply with study procedures. Participants were screened for age, 
body mass index (BMI) and physical activity levels to ensure a range of these characteristics. The study was approved by the Human 
Research Ethics Committees at The University of Sydney (08-2011/14053) and The University of Queensland (2011000931). All 
women provided written informed consent. 
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Study design 
At the baseline assessment, anthropometric measurements were taken and the participant ingested the initial dose of doubly labelled 
water. The participant was also fitted with three physical activity monitors; an Actigraph™, SenseWear® and ActiHeart®, and trained 
in the appropriate collection of urine samples for DLW analysis. Owing to battery and memory limitations of the monitors, a second 
visit occurred on Day 7 at a location convenient for the participant. The purpose of this visit was to ensure the DLW urine samples 
were being collected as instructed and to fit the participant with a new set of activity monitors. A final visit occurred on Day 14, at 
which point the monitors and urine samples were collected. 
Anthropometry 
Whilst the participant was wearing light clothing, body mass (kg) was recorded using a digital scale to the nearest 0.1 kg. A wall-
mounted stadiometer was used to measure height to the nearest 0.1 cm. Body mass index (BMI; kg•m-2) was calculated from these 
measurements.   
Reference method: doubly labelled water 
DLW was adopted as the reference method for measuring total energy expenditure (TEE). DLW procedures were conducted according 
to the International Atomic Energy Agency protocol [13]. A baseline urine sample was collected from each participant for the 
determination of the background isotope enrichment level of both oxygen 18O and deuterium 2H [14]. Participants were then given an 
oral dose of DLW (2H2O and H2
18O) based on their body mass. For each kg of body water, women ingested 0.083g 2H2 (99.8 atom % 
excess; Sigma Aldrich, Milwaukee, WI) and 2.083g 18O (10 atom % excess; Taiyo Nippon Sanso, Yokogawa, Japan). To calculate the 
actual dose administered, the drinking container was weighed before and after dosing. Each participant provided a urine sample at 
five hours following initial ingestion, with further samples on first voiding for the following fourteen days. Urine samples were stored 
at 4°C in the refrigerator at the participant’s home until collection by the researcher. The samples were then transferred to a -80°C 
freezer at The University of Queensland until analysed.  
All samples were analysed in duplicate at the Queensland University of Technology in the Energy Metabolism Laboratory. TEE (kcal•d-
1) was calculated using the multipoint method [13]. This involved calculating the 2H2 and 
18O dilution spaces and elimination rates.  
Sample 18O and 2H enrichment data were linearised using a logarithmic transformation; each data point had the background isotopic 
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enrichment subtracted and the loge value obtained. Data were plotted as loge sample enrichment versus time, linearity confirmed and 
elimination rates calculated [13]. 
Reference values for physical activity energy expenditure (PAEE) were calculated as 0.9 TEE – RMR [12]. This removed energy 
expenditure due to resting metabolic rate (RMR) and the thermic effect of food (assumed at 10% TEE) [12]. PAEE was defined as the 
calories a participant expended above resting energy expenditure. TEE was measured by DLW and RMR was assumed using the 
Schofield equations [15].  
Test methods: activity monitors 
Participants received an Actigraph™ (AG), SenseWear® (SW) and ActiHeart® (AH) at their first visit (Figure 1). They were instructed to 
wear the SW and AG for all waking hours, only removing them while sleeping and during water activities such as bathing and 
swimming. The AH was worn continuously for the whole data collection period. Participants received detailed written and oral 
instructions outlining the correct use of each activity monitor. Participants also kept a diary of when they removed each monitor and 
noted activities performed during the time of removal.  
 
Figure 1. Positioning of the ActiGraph™, Sensewear® and ActiHeart®  
 
Actigraph™ 
The Actigraph™ GT3x model is a triaxial accelerometer worn on the right hip. Data were sampled in 60s epochs and the Freedson 
VM3 equation was applied to raw Actigraph™ counts to calculate TEE [16]. As the Actigraph™ was removed when the participant 
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retired to bed, RMR for the equivalent period of time was added to TEE reported by the Actigraph™. This gave 24-hour data to enable 
comparison with DLW. PAEE was calculated as 0.9 TEE – RMR. RMR was assumed using the Schofield equations [15].    
SenseWear® 
 The SenseWear® is a multi-sensor monitor worn over the triceps brachii of the upper arm. A range of movement and physiological 
variables are captured by these sensors which continually collect information. Energy expenditure is estimated by combining these 
variables with sex, age, body mass and stature. The data were sampled at 60s epochs and used to estimate energy expenditure. The 
primary analysis was conducted with SenseWear® Professional Software Version 7.0 (BodyMedia Inc., PA, USA), with secondary 
analysis using Versions 8.0 and 8.1. No information is available on how raw data is processed using the SW proprietary algorithms.   
ActiHeart® 
The ActiHeart® consists of a two-lead electrode sensor system attached to the skin underneath the left breast. It contains a uniaxial 
accelerometer that measures bodily movements, combined with a pulse monitor to capture heart rate. These data are combined with 
sex, age, stature, body mass and sleeping heart rate to estimate energy expenditure. The data were sampled in 15s epochs and 
analysed using the group HR calibration model to estimate TEE and PAEE (ActiHeart® Software, Version 4, CamNtech Ltd, Cambridge, 
UK). The AH software uses the Schofield equation to estimate RMR [15].  
Missing activity monitor data 
Participants maintained a physical activity diary for the duration of the study. Women recorded the type and length of physical 
activity they participated in each day. If monitors were removed during a period of expected wear, the reason was noted. Where the 
AG or SW was removed for water activities, corresponding metabolic equivalent (MET) values were calculated using the compendium 
of physical activities [17]. All other gaps in data were filled with 1.5 METs.  
Data from each activity monitor were excluded from analysis if there were more than 2 full days missing over the 14 day period. 
Participants with 1 or 2 days missing were assigned the same TEE as another day of similar physical activity, as documented in the 
physical activity diary.     
Statistical analyses 
Descriptive statistics were used to describe the population and to assess mean and differences of mean TEE and PAEE estimates from 
the test and reference methods. Repeated measures analysis of variance (ANOVA) and post hoc tests were used to determine 
104 
 
whether there was a significant difference in energy expenditure between the test and reference methods. The agreement between 
measurements obtained with test and reference methods were analysed using Lin’s concordance correlation [18] and Bland-Altman 
plots with their associated limits of agreement [19]. Mean absolute percentage error (MAPE) of each of the test methods compared 
with the reference method was calculated to determine the degree of disparity with the following formula: ((mean difference test 
method-reference method)*100)/reference method [20]. Percentage similarity data pairs for each test method compared with the 
reference method were calculated using the formula: (((reference method+ test method)/2)/reference method)*100. Percentage 
similarity histograms allow visual comparison between methods with the highest peak showing the greatest accuracy and the 
narrowest spread showing the best precision between method pairs [21]. At the time of data collection, SenseWear® Professional 
Software Version 7.0 was available. Since then Versions 8.0 and 8.1 have been released; a secondary analysis was therefore 
undertaken in which TEE and PAEE were derived from these later versions. For all tests, significance was set at p<0.05. Means are 
presented as mean ± standard deviation (SD) unless otherwise stated.  
Results 
Participant characteristics are presented in Table 1. Participants ranged in age from 51 to 76 y, with a mean age of 60.7 (7.1) y. On 
average, women were overweight with a body mass of 72.0 (14.4) kg and body mass index of 26.9 (5.0) kg•m-2 (range 19.2 – 41 kg•m-
2). The most common comorbid conditions were osteoarthritis (27%), cancer (21%) and high cholesterol (21%).  
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Table 1. Characteristics of participants 
 
Characteristic  Age Group (y; n) 
 50-<60 60-<70 70+ 
Age (y; mean (SD)) 60.7 (7.1) 19 9 5 
BMI (kg•m-2; n)     
18-<25 (Healthy weight) 10 7 2 1 
25-<30 (Overweight) 20 2 7 0 
30+ (Obese) 3 1 3 1 
Activity level* (n)     
Low  9 4 2 3 
Moderate 18 10 6 2 
High 6 5 1 0 
Comorbidities (n)     
Cancer 7    
Heart disease 0    
Hypertension 5    
High cholesterol 7    
Diabetes 1    
Asthma 0    
Depression/anxiety 4    
Osteoarthritis 9    
Osteoporosis/osteopenia 4    
Thyroid problems 6    
*Determined by the International Physical Activity Questionnaire (IPAQ); BMI = body mass index. 
 
Missing physical activity data 
Total energy expenditure, as measured by DLW, was obtained for all 33 participants. Owing to subject compliance and technical 
issues, some data from the SenseWear® (n=1), ActiHeart® (n=5) and Actigraph™ (n=3) were determined as invalid. There was no 
pattern with respect to age, BMI or physical activity level between those who did or did not have valid data.  
Total energy expenditure (TEE) 
Estimates of TEE from DLW, AG, SW and AH are shown in Table 2. A repeated measures ANOVA determined that mean TEE did not 
differ significantly amongst DLW and the physical activity monitors (p=0.07). The test method with the highest level of agreement 
with DLW was the AG (rc=0.74). The SW agreed least with DLW on TEE (rc=0.49). 
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Table 2. Energy estimates for reference and test methods 
    Agreement  
 n Mean ± SD Range rc 95% CI MAPE* 
TEE       
Reference (TEEDLW) 33 2437 ± 359 1827-3455 
   
TEESW^ 32 2285 ± 311 1770-2896 0.49 0.26 to 0.67 6.2 
TEEAH^ 28 2269 ± 341 1805-3004 0.57 0.33 to 0.73 6.9 
TEEAG^
∆ 30 2280 ± 402 1736-3108 0.74 0.59 to 0.85 6.4 
PAEE       
Reference (PAEEDLW) 33 814 ± 218 296-1298    
PAEESW^ 32 486 ± 250 153-1072 0.00 -0.15 to 0.15 40.3 
PAEEAH^ 28 680 ± 244 274-1408 0.30 0.04 to 0.52 16.5 
PAEEAG^
Ⱡ 30 678 ± 266 298-1208 0.52 0.31 to 0.69 16.7 
TEE= total energy expenditure, subscript indicates monitor, SW = SenseWear®, AH = ActiHeart®, AG = Actigraph™; PAEE = physical 
activity energy expenditure, subscript indicates monitor, SW = SenseWear®, AH = ActiHeart®, AG = Actigraph™, *mean absolute 
percentage error ^TEE/PAEE provided by device ∆RMR added to account for sleeping ⱠDerived from TEEAG using 0.9 TEE-RMR 
 
For TEE, the MAPEs were similar for all monitors (SW=6.2, AH=6.9 and AG=6.4; Table 2). Secondary analysis of SW software versions 
demonstrated MAPEs ranged from 6.2 with Version 7 to 9.5 with Version 8.1, indicating Version 7 possessed the least error (Table 3).  
 
Table 3. Energy estimates for reference and SenseWear® software Versions 7, 8 and 8.1 
 
 Mean ± SD Range MAPE* 
TEE    
Reference (TEEDLW) 2437 ± 359 1827-3455  
TEESW7 2285 ± 311 1770-2896 6.2 
TEE SW8 2233 ± 326 1728-2894 8.4 
TEE SW8.1 2205 ± 290 1717-2880 9.5 
PAEE    
Reference (PAEEDLW) 814 ± 218 296-1298  
PAEE SW7 486 ± 250 153-1072 40.3 
PAEE SW8 358 ± 227 19-805 56.0 
PAEE SW8.1 317 ± 193 22 -701 61.1 
TEE= total energy expenditure, subscript indicates monitor, SW = SenseWear®, AH = ActiHeart®, AG = Actigraph™; PAEE = physical 
activity energy expenditure, subscript indicates monitor, SW = SenseWear®, AH = ActiHeart®, AG = Actigraph™; *mean absolute 
percentage error 
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Figure 2 shows a higher degree of accuracy and precision for the AH and AG compared to SW for estimates of TEE. Bland-Altman plots 
reveal the difference between DLW and the test methods (y-axis) against the average of each method and DLW (x-axis) (Figure 3). The 
narrowest limits of agreement were for AG (range: 1043 kcal•d-1, 44% of mean) and slightly higher for AH (range: 1094 kcal•d-1, 46% 
of mean). Values were higher still for SW (range: 1301 kcal•d-1, 55% of mean). All test methods underestimated TEE by 6% compared 
to DLW at the group level with no evidence of proportional systematic bias.  
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Figure 2. Percentage similarity histograms of total energy expenditure and physical activity energy expenditure measured by each 
device versus doubly labelled water.  The 100% similarity reference line is indicated in each plot.  
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Figure 3. Bland-Altman plots showing the differences in the mean total energy expenditure and physical activity energy expenditure 
between each device and doubly labelled water.  
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Physical activity energy expenditure (PAEE) 
Mean values and ranges of PAEE from DLW and the test methods are shown in Table 2. A repeated measures ANOVA determined that 
mean PAEE differed significantly amongst monitors (p<0.01). Post hoc tests revealed a significant difference between DLW and SW 
(p<0.01) but not between DLW and AG (p=0.07) or DLW and AH (p=0.13). 
A poor level of concordance between PAEE measured by the test and reference methods was observed (Table 2). AG had the highest 
level of agreement (rc=0.52) and SW the least agreement (rc=0.00). 
For PAEE, the MAPEs for the AH and AG relative to DLW were similar (16.5 and 16.7 respectively; Table 2). The SW demonstrated a 
much larger degree of error (40.3). Whilst all versions of SW software revealed a high MAPE (Table 3), Version 7.0 provided the 
smallest degree of error (SW7=40.3 v SW8=56 v SW8.1=61.1). 
The percentage similarity histograms present the underestimation of all three monitors compared to DLW (Figure 2). Figure 3 shows 
limits of agreement were similar for AG (range: 911 kcal•d-1, 127% of mean) and AH (range: 962 kcal•d-1, 130% of mean) and much 
higher for SW (range: 1320 kcal•d-1, 200% of mean). PAEE obtained from DLW was underestimated by all test methods, ranging from 
17% in AH and AG to 40% in SW. There was no evidence of proportional bias across the range of measured PAEE.  
Discussion   
This study was unique in its assessment of the validity of three physical activity monitors to estimate energy expenditure exclusively 
in women over 50 years under free-living conditions. Understanding the accuracy of monitors such as the Actigraph™, SenseWear® 
and ActiHeart® is important for physical activity and population health researchers and clinicians. All three monitors provided 
estimates of TEE similar to DLW, however, demonstrated large error and variability for estimates of PAEE. The findings of this study 
support the use of physical activity monitors for group-level estimates of energy expenditure but emphasise the need for caution in 
use of monitors dependent on the energy outcome of interest.    
Previous investigations of TEE or PAEE captured by the Actigraph™, SenseWear® and ActiHeart® compared to DLW under free-living 
conditions are summarised in Table 4. There are large variations in accuracy depending on the outcome of interest, population, device 
model and version of software used.  
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Table 4. Findings from previous validation research comparing doubly labelled water with the Actigraph™, SenseWear® and ActiHeart® 
Model 
(software/equation)* 
Citation EE reported n Population Findings  
 
Actigraph 
AM7164 (F, N, H1, H2, 
SW, L, Y1, Y2) 
Leenders [22] TEE 13 Females, 21-37y B TEEF:-21%, TEEH1:-21%, TEEH2:-2%, TEES:-4%, TEEN:-
20%, TEEL:-10%, TEEY1:-32%, TEEY2:-25% 
MTI/CSA (E, P) Reilly [23] TEE 85 Children, 3-6y B TEEE:5%, TEEP:-5% 
GT1M (C, C+LPF) Rotheny [24] TEE 22 Adults, 20-67 B TEEC:6%, TEEC+LPF:-2% 
GT1M (H, S, F) Assah [25] PAEE 33 African adults, 25-50y B PAEEH:23%, PAEES:23%, PAEEF:-6% 
GT1M (C,F)  Colbert [26] PAEE 56 Adults, 65+ y  M PAEEC: 23%, PAEEF:24% 
Actiheart 
(HRG) Rousset [27] TEE 41 Adults, middle-aged M TEE:13% 
(HRS) Farooqi [9] TEE, PAEE 19 COPD females, 59-80y B TEE:-9%, PAEE:-35% 
(HRS, HRG) Silva [11] TEE, PAEE 17 Males, 20-38y B TEEHRS:3%, TEEHRG:8%, PAEEHRS:-20%, PAEEHRG:-10% 
(HRG) Villars [28] PAEE 35 Males, 18-55y B PAEE:-9% 
(HRS, HRG) Assah [29] PAEE 33 African adults, 25-50y B PAEEHRS:-5%, PAEEHRG:-9% 
(HRS) Lof [30] PAEE 20 Females, 22-45y B PAEE:15% 
Sensewear      
Pro 2 (v5.1, v6.1) Arvidsson [31] TEE 20 Children, 14-15y B TEE5.1:9%, TEE6.1:-6% 
Pro 2 (v5.1, v6.1) Backlund [32] TEE 22 Obese children,  8-11y B TEE5.1:-<1%, TEE6.1:-18% 
Pro 3 (v6.1) Brazeau [33] TEE 20 Adults, 18-45y B TEE: 3% 
Pro 3 (v6.1) Koehler [34] TEE 14 Male endurance athletes B TEE:-2% 
Pro 3 (v6.0) Rousset [27]  TEE 41 Adults, middle-aged M TEE:9% 
Mini (v7) Calabro [35] TEE, PAEE 29 Adults, 60-78y M TEE:8 %, PAEE:28% 
Pro 3, Mini (v5.0) Calabro [36]  TEE, PAEE 28 Children, 10-16y M TEEP3:11%, TEEM:12%, PAEEP3; 30%, PAEEM:29% 
Pro 2  (v5.1, v6.1) Farooqi [9] TEE, PAEE 19 COPD females, 59-80y B TEE5.1:<1%, TEE6.1:-9%, PAEE 5.1:-12%, PAEE6.1:-35% 
Pro 3, Mini (v6.1) Johannsen [8] TEE, PAEE 30 Adults, 24-60y B TEEP3:-4%, TEEM:-1%, PAEEP3:-22%, PAEEM:-21% 
(v5.1, v6.1) Mackey [37] TEE, PAEE 19 Adults, 70-79 B TEE5.1:1%, TEE6.1:-1%, PAEE5.1:-19%, PAEE6.1:-27% 
Pro 2 (v5.1, v6.1) Slinde [38] TEE, PAEE 62 Lactating females, 24-41y B TEE5.1:3%, TEE6.1:-8%, PAEE5.1:-1%, PAEE6.1:-59% 
(v7) Tanhoffer [39] TEE, PAEE 14 Spinal cord injury, 23-65y B TEE:16%, PAEE:- 3% 
Pro 3 (v5.12) Colbert [26] PAEE 56 Adults, 65+ y M PAEE:27% 
112 
 
*not complete for all devices as information not specified in original article, B=bias, M=mean absolute percent error (MAPE), E=Ekelund, P=Puyau, C=Crouter, 
F=Freedson, C+LPF=Crouter plus low-pass filter, N=Nichols, H1=Hendelman 1, H2=Hendelman 1, SW=Swartz, L=Leenders, Y1=Yngve 1, Y2=Yngve 1, HRS= individual 
step test calibration of heart rate, HRG= group heart rate calibration, TEE=total energy expenditure, PAEE=physical activity energy expenditure, P3=Sensewear Pro 
3, M=Sensewear Mini 
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Actigraph™ 
The Actigraph™ is one of the most widely used and investigated physical activity monitors. However, this is the first study to our 
knowledge to examine the accuracy of the triaxial Actigraph™ GT3x in true free-living. The Actigraph™ possessed a reasonably small 
bias when estimating TEE. This is consistent with a study of 22 adults demonstrating comparability between the preceding GT1M 
model and DLW, which found the Actigraph™ had a bias between -2% and 6% [24]. In contrast to the reasonable estimates of TEE, a 
considerably larger error was observed in estimates of PAEE. Previous studies comparing PAEE from the GT1M to DLW reported a 
MAPE of 24 in adults aged over 65 [26] and bias ranging from 23% to -6% in African adults [25]. The smaller magnitude of error 
associated with the measurement of TEE compared to PAEE by the GT3x is consistent with the trend seen in the earlier GT1M model 
[24-26].  
Equations used by the Actigraph™ GT3x differ to those adopted for earlier uniaxial models such as the GT1M. The GT3x VM3 cut-
points used in this study were developed in a group of 50 healthy young adults in a laboratory setting [16]. They were obtained using 
a protocol of treadmill running and walking, demonstrating good relative validity with indirect calorimetry [40]. The developers of 
these cut-points acknowledge that they may not be generalisable to other age groups, especially older adults [16]. The also noted 
that these equations may not detect light intensity or sedentary behaviour [16]. Our findings of underestimation of energy 
expenditure confirm that the VM3 cut-points based on treadmill activity may not directly apply to energy expenditure estimation in 
free-living. Many activities of daily living involve only minimal acceleration at the waist, limiting the activities detected by the device. 
Despite these limitations, our findings showed the Actigraph™ GT3x provided a reasonable estimate of energy expenditure in older 
women. Further improvement of the algorithms, particularly with respect to PAEE, is necessary for improving the accuracy of the 
Actigraph™.  
SenseWear® 
Consistent with previous research, the SenseWear® underestimated TEE and PAEE. A study of older adults aged 60-78 years, using the 
same version of software as the present study, observed a similar-sized MAPE (8) for TEE compared to DLW [35]. Studies examining 
TEE captured by the SenseWear® in younger adults [8, 33] and athletes [34] report biases between -4% and 3%, smaller than those 
seen in older populations. The accuracy of TEE captured by the SenseWear® varies considerably across clinical populations, with bias 
ranging from -18% in obese children [32] to 16% in spinal cord injury [39]. Given the original SenseWear® algorithms were developed 
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in predominantly healthy younger adults, the extrapolations adopted to provide estimates for other populations may explain the 
varying levels of accuracy across cohorts [41]. Additional work on the SenseWear® is required to develop specific algorithms to 
accurately estimate total energy expenditure in older adults.  
Similar to the Actigraph™, the SenseWear® was less accurate estimating PAEE than TEE. This is consistent with a recent study of older 
adults which reported a much larger MAPE for PAEE compared to TEE (28 vs. 8, respectively) [35]. Similarly, large underestimations of 
PAEE are also evident in comparisons of older models of SenseWear® with DLW. Investigations in older adults have reported bias of -
27% [37] and a MAPE of 27% [26]. Comparable patterns of findings are also evident in other populations including children [36] and 
older women with COPD [9]. The consistent underestimation of PAEE by the SenseWear® suggests that the default threshold used for 
the classification of PAEE may be too high, and possibly fails to capture physical activity carried out at low intensity.  
The SenseWear® estimates of energy expenditure were most accurate using software Version 7.0 (MAPEs: TEESW7=6.2 vs. TEESW8=8.4 
and TEESW8.1=9.5). Owing to the proprietary nature of the algorithms used to transform sensor data into energy expenditure, the 
changes implemented between versions of software are not transparent and it is not possible to identify specific features of the 
equations. Whilst previous research has not compared the versions used in this study, similar observations have been made with 
earlier versions. In one study of obese children [32] using software Versions 5.1 and 6.1, TEE was more accurately captured in the 
earlier version of the software (v5.1: -<1% vs. v6.1:-18%). Similarly, a study of older women with COPD also found large differences in 
estimates of PAEE (v5.1: -12% vs. v6.1:-35%) [9]. Findings suggest that updates to software may not necessarily improve the validity of 
assessing energy expenditure and could actually reduce accuracy. Researchers should consider this when selecting which software to 
use and not assume that the most recent version is the most appropriate for the outcome or population of interest.  Furthermore, the 
variation between versions also makes comparison across studies using different monitors and software difficult. 
ActiHeart® 
The ActiHeart® has not been examined as extensively as other available physical activity monitors. There have been no studies to date 
that compare energy expenditure from the ActiHeart® to DLW in healthy older adults. However, our finding that the ActiHeart® 
underestimates TEE is supported by a study of 19 older women with COPD which reported a similar bias (-9%) [9]. These findings are 
in contrast to a study of physically active young men which reported the ActiHeart® overestimated TEE by 8% [11]. Comparisons of 
PAEE obtained by the ActiHeart® to DLW have presented similarly variable findings, ranging from an underestimation of 35% in 
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women with COPD [9] to an overestimation of 15% in young females [30]. Studies of males under 55 y [11, 28] and African adults [29] 
have compared more favourably with underestimations of PAEE of 8-10%. These healthy adult populations [11, 28, 29] possess higher 
levels of daily energy expenditure than women with COPD [9] and those in this study, whose movement occurs primarily at the lower 
end of the activity spectrum. These data suggest that lower levels of activity observed in older and clinical populations may impact 
the ability of the ActiHeart® to accurately estimate PAEE. This is further supported by an investigation comparing the ActiHeart® to 
indirect calorimetry where it was seen that the ActiHeart® was better able to predict energy expenditure during physical activity than 
sedentary behaviour [10]. A study in children similarly found no correlation between the ActiHeart® and sedentary behaviour, 
observing it only becomes accurate with activities above 2.5 METs [42]. As with the Actigraph™, this may be the result of the 
equations being developed with treadmill walking and running in controlled laboratory conditions [10], limiting the applicability to 
other activities of free-living.  
The manufacturer currently recommends conducting a step test during setup of the ActiHeart® for individual calibration and 
subsequently increased accuracy. However, we were unaware of this feature at the time of data collection so this approach was not 
utilised. Previous studies that have adopted individual calibration have reported varying degrees of validity. One study of 17 young 
males which compared individual calibration to standard group calibration, reported that individual calibration was more accurate for 
TEE but not PAEE [11]. Findings from a study of African adults provided conflicting results, demonstrating that individual calibration 
resulted in a lower error for PAEE and was, therefore, beneficial [29]. Whether individual calibration of the ActiHeart® in this study 
would have provided a more accurate estimation of energy expenditure than group modelling is not clear.  
Comparison of SenseWear®, Actigraph™ and ActiHeart® 
Whilst the monitors likely overestimated or underestimated energy expenditure during various activities, all three monitors provided 
good overall approximations of TEE. This is particularly impressive given the difficulties in capturing physical activity in free-living and 
that these monitors are primarily validated in laboratory conditions. Although DLW is a highly acceptable reference method for 
measuring energy expenditure in free-living, there are potential sources of error which must be considered when interpreting 
validation results. Given the measurement error of DLW is 5-10% [5], the underestimation of TEE by 6% means it is plausible that all 
three monitors are able to reasonably predict TEE at the group level. However, the wide limits of agreement and absence of 
proportional systematic bias indicate a considerable random error and large variability for individual estimations. The use of any of 
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these physical activity monitors may be suitable for group level estimations of TEE, however, may lead to misclassification of physical 
activity levels in individuals.  
The performance of the monitors for estimating PAEE was poor in comparison to TEE.  All three monitors underestimated PAEE, likely 
contributing to the underestimation of TEE. The equations used to estimate energy expenditure in these monitors were developed 
predominantly using young active adults who were required to run or walk on a treadmill [10, 16, 43]. As such, the underestimation 
of PAEE may suggest a limited ability to discriminate light from sedentary activity, which is more difficult to detect than activities of 
higher intensity. Given a large amount of time is spent sedentary and in light activity over a day, the inability to distinguish would add 
considerable error over time [44]. As RMR is calculated predominantly from participant characteristics and alone can account for 60-
80% of TEE [45], it is not surprising that there is a comparatively low error for measuring TEE compared to PAEE. 
Each of the three monitors holds a different position in the marketplace, particularly with respect to cost. The Actigraph™ is the 
cheapest, with the SenseWear® and ActiHeart® more than three times its price.  Whilst the presence of multiple physiological sensors 
in the SenseWear® and ActiHeart® should theoretically improve the precision of energy expenditure estimates, they did not show any 
improvement in accuracy compared to the single-sensor Actigraph™. Although the ActiHeart® performed similarly to the Actigraph™, 
the number of technical and compliance issues that arose with the ActiHeart® should be considered. In addition to energy 
expenditure, these monitors are also able to capture other measures of physical activity. As such, these devices may be beneficial for 
assessment of other outcomes such as steps taken, sedentary behaviour and intensity of physical activity, although these were not 
evaluated in this study. Given the varying price points and findings of this study, the Actigraph™ may be the preferred tool of choice 
for researchers when examining free-living energy expenditure in older women.  
The use of doubly-labelled water as the reference method allowed for the validity of the Actigraph™, SenseWear® and ActiHeart® to 
be assessed concurrently. It is important however that the PAEE data be interpreted with caution as RMR was not measured but 
instead estimated using Schofield equations [15]. As the Actigraph™ and SenseWear® were removed in the evening, assumptions that 
the participant was resting during this time may have led to underestimations of energy expenditure. As is the case in the constantly 
evolving field of objective physical activity monitoring, the conclusions presented are applicable only to the device models and 
software versions used in this study.  
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At the group level, the Actigraph™, SenseWear® and ActiHeart® demonstrated acceptable levels of agreement with a reference 
measure of TEE in older women in free-living conditions. All monitors had a better agreement for estimates of TEE compared with 
PAEE. Further research is required to advance the ability of these monitors to accurately capture PAEE. Based on the accuracy and 
cost of the three monitors, the Actigraph™ may be the preferred tool for estimating energy expenditure in this population. When 
considering the use of a physical activity monitor, researchers and clinicians should not only consider the desired outcome when 
choosing a device to collect data but also the data processing method adopted.   
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Chapter 6: 
Concluding remarks 
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Overview of main findings 
This thesis investigated important issues of physical activity and exercise in women with metastatic breast cancer with a view to 
addressing important gaps in the literature. Chapter 1 provided a background to breast cancer and explored available treatments for 
metastatic disease and associated side effects. Previous research into the role of physical activity across the breast cancer continuum 
was presented, which demonstrated that the benefits for women with early stage cancer are well understood [1-17]. In contrast, 
there is little information on its role for women living with metastatic disease. Six randomised controlled trials [18-23] were identified 
across all metastatic populations, of which five were deemed high quality [18-22]. Seven additional studies were located, describing 
uncontrolled trials or case reports. Resistance training interventions were conducted in three of the high-quality studies, with 
promising results observed for improving physical function and decreasing fatigue [18, 19, 22]. Gaps in the understanding of physical 
activity for this population were identified, leading to the program of research reported herein. The broad aims of this thesis were to 
determine the physical capabilities and interests for physical activity of women living with metastatic breast cancer and to use this 
knowledge to develop and pilot an appropriate physical activity intervention. In addition, it was identified that the accuracy of body-
worn monitors for measuring physical activity in this older age group was largely unknown, which led to the design of the final study 
in which the accuracy of three physical activity monitors was determined.  
To design a physical activity intervention for women with metastatic breast cancer, an understanding of the physical capabilities of 
the population is first required. The presence of symptoms and subsequent decline in quality of life has been described in women 
with metastatic disease [24-26], however, the physical status of the population is unclear. The findings from Chapter 2 described 
physical activity levels and fitness of women with metastatic breast cancer, along with their physical and psychosocial well-being. To 
further understand the impact of metastatic disease, women were compared to an age-matched cohort of women without metastatic 
cancer. Not surprisingly, women with metastatic disease possessed significantly lower levels of aerobic fitness and strength when 
compared to an age-matched healthy cohort. The women with metastatic disease were also more sedentary, completing around half 
as much physical activity as their healthy counterparts. Whilst overall the cancer group was deconditioned, some women with 
metastatic disease demonstrated a higher level of fitness and activity than their healthy peers. Unexpectedly we found that 
approximately 30% of women with metastatic breast cancer possessed aerobic fitness levels above average for their age. This 
highlighted the heterogeneity and wide range of physical abilities of the metastatic breast cancer cohort. 
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Another finding drawn from Chapter 2 was that women with metastatic breast cancer reported lower functional status than healthy 
women across all domains: global, physical, role, emotional and social. In addition, they demonstrated higher symptom burden, 
experiencing greater levels of pain, nausea, dyspnoea, constipation, diarrhoea and appetite loss than the age-matched healthy 
cohort.  Although as a group the women with metastatic disease reported poor quality of life, many presented with minimal 
symptoms related to their cancer. Overall this cohort reported higher levels of functioning and lower symptom burden than other 
studies of women living with metastatic disease, indicating this cohort may be functioning higher than the average woman living 
metastatic breast cancer.  
With some insights gained into the physical status of the metastatic population, an intervention could be developed in which women 
were capable of participating. However, given that adherence to physical activity may be particularly challenging for cancer patients 
[27], consideration of activity interests and preferences is also important for maximising acceptance and efficacy in this unique 
population. Interviews revealed that the majority of women living with metastatic breast cancer were interested in a physical activity 
program (Chapter 3). Women demonstrated a strong preference for home-based activity, with walking being their preferred exercise 
modality. Women also favoured a range of other activities including swimming and resistance training. The strong interest, coupled 
with demonstrated physical capacity, demonstrated feasibility for a physical activity program for women living with metastatic breast 
disease.  
With most studies excluding women with metastatic breast cancer, little data exist on the safety and feasibility of physical activity 
interventions in this population. As the first step in addressing this gap, an intervention was developed with knowledge gained from 
Chapters 2 and 3. An 8-week home-based multi-mode program was delivered within a randomised controlled intervention (Chapter 
4). An Exercise Physiologist attended the participant’s home twice a week to supervise resistance training sessions. Women were also 
asked to walk on days of the week they were not seeing their exercise trainer, with the aim of increasing the number of steps taken 
each week by at least 10%. An important finding of this study was that no adverse events related to the intervention were noted.  
The feasibility of supervised resistance training was demonstrated through high recruitment rates and 100% adherence and 
compliance to training sessions. The adherence and compliance rates for this component were higher than previous research, which 
may have been influenced by the external motivator of an Exercise Physiologist turning up at the front door for each session, along 
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with the consideration of physical activity preferences in designing the intervention for this unique population. Overall, supervised 
resistance training was shown to be safe and acceptable for women with metastatic breast cancer.  
Adherence to the walking component was poor, with only two women completing the prescribed number of training sessions. To 
allow for further analysis of adherence data, women were divided into three groups based on adherence rate to the walking program; 
low (0-49%), moderate (40-89) and high (≥90%). When grouped by ECOG performance status, this revealed that the most adherent 
women were high functioning and active with no limitations due to their disease (ECOG 0; Figure 1) [28]. All of the women who 
achieved a moderate level of adherence were classified as ECOG 1, ambulatory and able to carry out light activity. The poorest level of 
adherence was seen in the lowest functioning participant with an ECOG of 2,i.e.  ambulatory but unable to carry out any work 
activities. As some women exhibited physical impairments limiting activity, it is possible that these women were not physically 
capable of achieving the prescribed dose of the walking program.  
Figure 1. Adherence to the walking program grouped by ECOG performance status. Values are mean and standard error.  
 
 
The majority of women were compliant with walking at a moderate intensity, however, no participants successfully increased their 
steps by 10% each week. Despite the poor compliance to walking volume, some women did increase steps above baseline levels 
(Figure 2). If women had increased steps by 10% per week as prescribed, the number of steps taken in Week 1 should have doubled 
by Week 8. Four women increased weekly steps throughout the intervention, with three women more than doubling their Week 1 
step counts in Week 8. Adherence to the walking program was higher in those who were more active but did not predict which 
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women increased weekly step counts. Despite overall poor adherence to the walking program, the majority of women improved their 
walking capacity throughout the intervention (Figure 3). The increase in six-minute walk test distance ranged from 6-9% in the women 
with low adherence, which did not differ from the mean change in those with higher adherence. Although adherence to the walking 
component of the physical activity intervention was poor, most women still obtained some benefit to their physical function.    
Figure 2.Steps taken per week by each participant during Weeks 1 and 8. * represents steps more than doubled during the intervention 
 
Figure 3.Change in six-minute walk test from Baseline to Week 8 for each participant. There is missing data for one control.   
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All women who completed exercise training had previously indicated interest in physical activity, (Chapter 3) prior to enrolling in the 
randomised controlled trial. Data were examined in the context of this information to identify any indicators of poor adherence. As 
part of the interview, a snapshot of self-efficacy was obtained by asking women to rate to what extent they were confident in their 
alibility to increase physical activity on a scale from 0 to 10, with 10 being extremely confident. Responses to this question appear 
related to adherence to the unsupervised walking program (Figure 4). Women with high or moderate adherence were generally 
confident about their ability to increase physical activity. The two women with low adherence reported low confidence, with scores of 
3/10 and 5/10. Adherence was further examined with respect to individual preferences for physical activity (Table 1). Both low 
adherent participants expressed a preference for a home-based program with walking which comprised part of the intervention that 
was delivered. Although only half of the women indicated resistance training as a preference, high adherence and compliance to this 
component was observed. In summary, women with low levels of self-efficacy for undertaking physical activity were less likely to 
adhere to the unsupervised walking program, despite identifying this mode as a preference for activity.  
Figure 4. Confidence in ability to increase physical activity vs. adherence to the unsupervised walking program. There is missing data 
for one participant.  
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Table 1. Physical activity preferences in low, moderate and high adherers to the walking program. Values are n.  
 Adherence^ 
 
Low 
(n=2) 
Moderate 
(n=4) 
High 
(n=2) 
If you were to participate in a physical activity program, in what 
environment/s would you prefer to perform exercise? 
   
At home 2 2 1 
If you were to participate in a physical activity program, what 
type of exercise would you like to perform?* 
   
Walking 2 1 2 
Resistance training 1 1 2 
^ Low=0-49%, Moderate=50-89%, High=≥90% *Participants may have selected multiple responses 
 
In addition to being generally well-tolerated, the intervention also provided promise for improving physical function and reducing 
symptoms. Although the sample size was not powered for probability testing, positive changes were observed for aerobic fitness and 
muscle strength. Improvements were also observed in patient-reported outcomes, including social and role function, and symptoms 
of fatigue and pain. These preliminary findings provide a platform from which larger trials can be developed to explore the optimal 
mode, frequency, intensity and duration of exercise for women living with metastatic breast cancer.  
The quantification of physical activity levels was central in describing habitual physical activity (Chapter 2) and changes to physical 
activity as a result of a lifestyle intervention (Chapter 4). Physical activity monitors are often favoured for this kind of research due to 
their affordability and practicality. However, many of these devices were have been validated in a laboratory under controlled 
conditions, with limited data to support their use in a free-living environment for women of a similar age as those with metastatic 
breast cancer. The accuracy of Actigraph™, SenseWear® and ActiHeart® physical activity devices in older women in free-living was 
explored in Chapter 5. This was achieved by comparing energy expenditure estimated by each device to the reference method of 
doubly labelled water.  All three devices presented acceptable estimates of total energy expenditure but demonstrated a larger error 
when capturing physical activity energy expenditure. Of the three monitors, the Actigraph™ was recognised as the preferred tool for 
measuring energy expenditure in women over 50 years, owing to its comparatively superior performance and reduced cost.   
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Clinical implications 
As research on the role of physical activity for women with breast cancer has historically focused on early stage disease, it has created 
gaps in the scientific knowledge about its role for those living with metastatic spread. Exclusion of these women from interventions is 
due to fear of skeletal-related events and the presence of symptoms such as fatigue and cachexia [29, 30]. Clinicians are reluctant to 
encourage physical activity for the same reasons [30], despite recommendations from the American College of Sports Medicine that 
individuals with metastatic disease should reduce sedentary behaviours and avoid an inactive lifestyle [31]. The challenge for 
researchers is therefore not only to address gaps in the evidence but also to change clinical thinking as supporting evidence continues 
to emerge. 
The most valuable finding of this program of research was that a partially supervised home-based physical activity intervention is safe 
and feasible for women living with metastatic breast cancer (Chapter 4). Preliminary evidence also suggested physical activity may 
provide benefit by improving function and quality of life, although further research is still required. Notwithstanding the uncertain 
role of physical activity in metastatic breast cancer, its role in managing and preventing other comorbidities alone warrants 
encouragement by clinicians for their patients. Advice on physical activity is likely to be well received given that most women with 
metastatic breast cancer are interested in being physically active (Chapter 3). Disinterest in physical activity was not related to being 
unwell, so clinicians should not make assumptions about a patients’ willingness to participate based on health status. Oncologists, 
GPs, nurses and other multi-disciplinary team members can encourage participation in lifestyle physical activities like walking, with 
confidence that the safety risk is low. Participation in structured activity, such as resistance training, should also be advocated by 
clinicians and women referred to an exercise professional for the development of an appropriate program.   
Women with metastatic breast cancer represent a heterogeneous population, with many receiving well-tolerated treatments whilst 
others endure more toxic regimens due to aggressive disease. Recognition of the variability with respect to physical capacity and 
symptoms is important for all clinicians and exercise specialists in particular. Whilst some of the population were active and able to 
maintain their work and households roles, those at the lower end of the spectrum were sedentary and experienced high symptom 
burden (Chapter 2). Not only does physical ability vary across this continuum but the needs of the individual will also likely differ. A 
one-size fits all approach is therefore not appropriate for research and the implementation of patient-centred care is necessary for 
this unique population.  
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Whilst an exercise prescription developed outside of a clinical trial would ideally reflect more individual consideration, the delivery of 
a patient-centred approach in Chapter 4 was relatively successful. The strong preference women demonstrated for a home-based 
physical activity program guided the design of the intervention. During informal discussions, many women indicated this was a 
preference as they were already overwhelmed with medical appointments that consumed significant amounts of not only their time 
but also of caregivers. The majority of women nominated walking as the preferred type of activity. Although adherence to the walking 
program was lower than anticipated, several women did achieve substantial progress of walking their volumes throughout the 
intervention. In comparison, the interest in resistance training was somewhat lower but excellent adherence and compliance to the 
supervised component was observed. Thus, identification of physical activity preferences alone does not necessarily translate to high 
levels of adherence or compliance, and other programming considerations such as supervision may have an impact. Whilst the 
program was shown to be safe for this population, it should be noted that high-impact activities were intentionally avoided to 
minimise the risk of skeletal-related events [32] and are not recommended for inclusion. In conclusion, these findings support the 
implementation of a patient-centred approach by exercise specialists and provide an example of a safe exercise prescription.   
Adherence levels to the unsupervised walking program appeared to be influenced by physical performance status and an individual’s 
confidence in their ability to engage in physical activity. These factors did not appear to play a role in supervised resistance training as 
all women achieved excellent adherence and compliance to this component. With respect to the walking component, women with 
unrestricted function and a high level of self-efficacy demonstrated high adherence, suggesting that this subgroup of women does not 
require additional strategies to support participation in the unsupervised walking program. However, some women with lower levels 
of function and low self-efficacy had poor adherence to walking. To be adherent to the walking program, women needed to walk five 
days a week in addition to undertaking two resistance training sessions. For women with impaired function, the prescribed dose was 
likely too high and they were not physically capable of achieving it. A reduced frequency of walking may be more appropriate for this 
subset of women, commencing with two sessions per week with gradual progression over the duration of the intervention.  
Physical activity self-efficacy describes an individual’s expectation that they will be able to achieve the desired outcome. In Social 
Cognitive Theory, self-efficacy has been identified as a predictor of physical activity adherence, with high self-efficacy motivating 
behaviour [33]. Thus, it is not surprising that woman with low confidence in their ability to increase physical activity had difficulty 
adhering to the unsupervised walking program. However, adherence to resistance training in these women was excellent, suggesting 
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that supervision may assist in overcoming poor self-belief. To enhance self-efficacy, there are four sources of efficacy information to 
consider [34]. The most potent of these forms is ‘mastery experiences’ that reflect prior accomplishment and reinforce confidence in 
the ability to succeed again [34]. Ensuring success with small obtainable goals and avoiding the risk of failure by doing too much too 
soon is critical. In the context of the walking program, commencing with a reduced and achievable number of sessions would likely 
boost self-efficacy, and subsequently adherence. Additional strategies to build self-efficacy, such as education and goal setting, may 
further improve the ability of women to successfully participate in a physical activity program.      
 Although inclusion of exercise preferences likely had a large influence on adherence rates, the contribution of an Exercise 
Physiologist attending the participant’s home should not be underestimated. On days when women were feeling unwell or lacked 
motivation, they openly confessed they would not have completed the exercise of their own accord if the trainer had not arrived to 
motivate them. This is an important consideration for exercise specialists as it is not financially viable for most women to have 
supervision at every training session. Whilst further research is needed to investigate the success of tapering off supervision over 
time, strategies must be implemented for maintaining adherence. As social support plays a significant role in enhancing exercise 
adherence [35], one approach could be to partner each woman with an “exercise buddy”.  The identification of a friend or family 
member to exercise alongside may be seen as a motivating factor and will also assist in building self-efficacy. This peer support could 
be further supported with commercial wearable technologies, with devices like the Fitbit® (Fitbit Inc., San Francisco, CA) providing a 
fun and interactive way of monitoring physical activity. Such devices enable support through social media platforms in addition to 
tracking progress towards daily step goals, motivating individuals to keep moving. Innovative approaches that boost engagement are 
likely the key to maximising adherence during unsupervised training sessions.  
In addition to providing motivation for individuals to be active as previously discussed, wearable physical activity monitors also allow 
researchers to capture physical activity levels for the purposes of surveillance and describing the efficacy of interventions. The ability 
of monitors to accurately estimate physical activity and assess energy expenditure is essential. Even though monitors like the Fitbit® 
are attractive to the mass market, limited evidence exists about their validity [36]. For this reason, researchers still generally use 
physical activity monitors developed primarily for clinical research. If working with a population of older women, one of the most 
widely used devices, the Actigraph™, is recommended for use if the outcome of interest is energy expenditure.  The high cost of the 
SenseWear® and ActiHeart® is not justified as neither was more accurate than the relatively inexpensive Actigraph™. If researchers 
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already have access to SenseWear® or ActiHeart® monitors, their use is acceptable for determining estimates of total energy 
expenditure. However, if physical activity energy expenditure is the desired outcome, adoption of the ActiHeart® is satisfactory whilst 
the SenseWear® is not recommended.  It should be noted that all of these devices also provide information on other physical activity 
indicators not evaluated in this study. These monitors may have a role in capturing data such as steps taken, time in moderate-
vigorous intensity activity, and sedentary behaviour. 
The choice of physical activity monitor should be determined by the outcome of interest as well as the population being investigated.  
The accuracy of the Actigraph™, SenseWear® and ActiHeart® is highest in healthy young adults, the population typically used for 
development of devices and their associated algorithms for estimating physical activity [37]. A relatively small number of validation 
studies have been performed in other age groups and across clinical populations. Movement patterns of these groups can vary 
considerably, so without validation in the population of interest, the accuracy of monitors should not be assumed.  Findings from 
specific validation studies can potentially be extrapolated to other groups if metabolic profiles and movement patterns are known to 
be similar.  
Future directions 
The findings of this thesis extend the knowledge base relating to physical activity for individuals with metastatic cancer. Several 
questions have been addressed, however many aspects on the role of physical activity warrant further investigation. The safety and 
feasibility of a partially supervised home-based physical activity intervention has been demonstrated, but its effectiveness must now 
be established. Large randomised controlled trials with sufficient power would allow efficacy to be examined.  
As physiological adaptations generally start to occur within the first two months of exercise, an 8-week intervention should be 
sufficient to induce improvement in physical capacity. However, as adaptations continue beyond this point, a longer program may 
result in more substantial benefits. Although adherence to the resistance training component of the intervention in this thesis was 
excellent, supervision at every training session was likely a contributing factor. This design was important to ensure that the 
intervention was safe but required a significant amount of resources to conduct, reducing the feasibility of delivering a longer 
intervention and limiting the potential for translation into routine care. Given the absence of adverse events, it would appear feasible 
to safely scale back supervision over the duration of the program. A six-month program consisting of varying levels of supervision 
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would allow for longer term efficacy to be assessed with fewer resources than the current intervention. Such a model could entail 
supervision initially at each session, dropping to once a week after the first month, fortnightly during the third month and 
unsupervised sessions during the final three months. With reduced supervision, approaches such as the use of telehealth could be 
implemented to motivate participation and assist with progression. Development of a website or mobile phone application containing 
demonstrations of each exercise and short educational videos building skills related to exercise self-efficacy would further support 
and encourage women. Well-designed strategies encouraging self-management of physical activity may allow programs of extended 
duration to run without placing an increased strain on resources.   
Follow-up periods subsequent to physical activity interventions in metastatic populations are generally short. In this thesis, many of 
the benefits obtained from the intervention were maintained two months following the end of the program. However, it is unknown 
whether benefits would be sustained longer term. Assessments scheduled at 3, 6, 12 and 24 months post-intervention may provide 
insight into sustained benefits whilst considering participant burden. It should be acknowledged that recruitment into longer studies 
may prove difficult given the age and high disease load of the population. Eligibility criteria for enrollment may need to reflect survival 
for the duration of the intervention rather than completion of the study, with the recognition that some participants may be lost to 
follow-up as a result of death. Extended follow-up periods will provide a better understanding of the long-term benefits of physical 
activity.   
Further research is also needed to determine the optimal exercise mode for women living with metastatic disease. The physical 
activity intervention in Chapter 4 demonstrated that a combined resistance and walking program may be beneficial, although it is 
currently unclear which mode of physical activity is most efficacious. A pragmatic research design comparing resistance training, 
aerobic training, and resistance and aerobic training in combination, should be considered. This would determine which type of 
physical activity is best overall, as well as for addressing particular symptoms or side-effects. It is also unclear what exercise intensity, 
frequency and duration yield the largest benefits. However, it is likely that the optimal prescription will vary across the population, 
largely determined by an individual’s level of physical function.  
The linking of physical activity interests to findings from the intervention further highlighted the heterogeneity of the cohort and 
identified sub-groups of women. The ability of women to adhere to the prescribed physical activity program appeared largely related 
to their physical performance status. For future studies, it would appear beneficial to stratify women with metastatic breast cancer 
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into more homogenous groups. The use of a performance scale such as ECOG [28] to achieve this would result in the ability to deliver 
a more targeted intervention to each sub-group. Whilst women with ECOG 0-2 were included in the intervention described in Chapter 
4, this stratification may accommodate participation by women with even lower levels of function. Using this approach, women 
would be streamed into one of several interventions following baseline assessment. Women with an ECOG of 0 could commence with 
a program similar to that delivered in this thesis, with reduced resistance training supervision as the program progresses. However, 
women with an ECOG of 2 for example, would require adjustment to the prescribed dose of the walking program and would benefit 
from additional strategies to build self-efficacy. These low functioning women would also require closer monitoring of program 
adherence and compliance in comparison to those with a higher performance status.  
Although grouping of women into smaller homogenous subsets may lead to improved efficacy, appropriate tools for measuring the 
effect of the intervention are required. With the large variability in function across the population, traditional outcome measures may 
not be appropriate due to the potential of fixed-items being irrelevant to an individual’s needs. There are a number of patient-specific 
instruments measuring physical function, including the popular Patient-Specific Function Scale (PSFS) [38]. The PSFS allows patients to 
identify impairments that are most relevant to them, with outcomes focusing on the evaluation of these impairments over time.  
Another avenue warranting exploration is the health economics of physical activity as a therapy for improving well-being in 
metastatic breast cancer. The disease creates a significant economic and societal burden through direct costs of medical treatment 
and indirect costs such as loss of income and caregiver burden [39]. The debilitating effects of metastatic disease can also exacerbate 
existing health problems or promote further comorbidities, placing an additional burden on individuals and the health care system. 
Observations of quality of life and survival, along with information such as productivity, hospital admissions and drug prescription 
may provide a snapshot of the magnitude of costs of living with metastatic breast cancer. If exercise is shown to be a cost-effective 
strategy for managing metastatic disease, this may have a major role in shifting clinical practice.  
The accurate measurement of energy expenditure pre- and post-intervention is important for evaluating a physical activity program. 
Whilst the Actigraph™ is recommended for use in healthy women aged over 50 years, its accuracy in similarly aged women living with 
metastatic breast cancer is unclear. It is possible that the presence of a tumour or subsequent treatment may alter an individual’s 
metabolic profile or movement pattern, creating a relationship between activity and energy expenditure unknown to the device. Of 
the physical activity monitors designed for clinical research, future studies are required to determine which is most appropriate for 
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use in this population. In addition, consumer-wearable monitors like the Fitbit® should be included in further validation studies to 
determine their suitability as a research tool. Determination of the accuracy of physical activity monitors in women with metastatic 
breast cancer will allow for selection of the most suitable device for evaluating the efficacy of a physical activity intervention.  
Conclusion 
The limited understanding of the role of physical activity in metastatic disease is attributable to the exclusion of this population from 
clinical research. This omission is traditionally due to a perceived increase in safety risk and concern over symptoms. Findings in this 
thesis confirm that women living with metastatic breast cancer are interested and capable of being physically active. In addition, the 
intervention study offers further evidence to the small body of knowledge that partially supervised physical activity is safe for this 
population and may be beneficial for improving well-being. It is, therefore, time for more focus to be placed on the role of physical 
activity for metastatic populations. With respect to the accurate assessment of physical activity, this thesis recommends the use of 
the Actigraph™ in older women.  
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